

Subject Index

A

abatacept

- rheumatoid arthritis - Orencia (New drug) 30(6) 163-7

abnormal laboratory results (see also diagnostic tests)

- abnormalities in pregnancy 29(2) 48-52
 - letter 29(4) 91-3
- adrenocortical function in adults 30(6) 147-9
- antibodies to cyclic citrullinated peptides in rheumatoid arthritis 29(6) 162-4
- biochemical tests in pregnancy 28(4) 98-101
 - letters 29(1) 3-5; 28(6) 136-9
- cell markers 30(5) 128-9
- C-reactive protein 30(3) 74-6
- magnesium 30(4) 102-5
 - letter 30(6) 140-1
- multiple myeloma screening 32(4) 92-4
- paediatric biochemical tests 28(5) 126-9
- pitfalls in interpretation 32(2) 43-6
 - letter 32(5) 119-121
- sexually transmitted infections 30(1) 8-13
- therapeutic drug monitoring 31(2) 42-4
 - therapeutic range of digoxin (letter) 31(5) 115-8

abnormalities, congenital - see birth defects

Aboriginal people

- medication management 28(5) 123-5
 - letters 29(6) 149-50; 29(3) 59-62
- subsidised medicines 32(5) 121; 31(4) 89

abortion, therapeutic

- mifepristone 32(6) 152-4

ACAM2000

- see vaccinia smallpox vaccine 32(6) 165-171

acetylcholinesterase inhibitors

- donepezil in Alzheimer's disease (editorial) 28(6) 134-5
 - letter 29(3) 59-62

acne

- isotretinoin in cystic acne 28(3) 59-61
- tazarotene - Zorac (New drug) 29(3) 84-7

acromegaly

- drug treatment of pituitary tumours 32(1) 19-21

Actemra

- see tocilizumab 32(4) 112-5

ACTH - see adrenocorticotrophic hormone

acute-phase reaction

- C-reactive protein 30(3) 74-6

adalimumab

- in psoriasis 32(1) 14-8
- tumour necrosis factor blockers in rheumatology 29(3) 67-70

Addison's disease

- abnormal laboratory results 30(6) 147-9

ADHD - see attention deficit hyperactivity disorder

adrenaline

- management of anaphylaxis - wallchart 30(5) 115
- repeat prescriptions of EpiPen auto-injectors (PBAC question) 28(4) 90
- shelf-life of EpiPen (PBAC question) 29(2) 52-3

adrenocorticotrophic hormone

- abnormal laboratory results 30(6) 147-9

adverse effects (see also birth defects; drug interactions)

- Adverse Drug Reactions Advisory Committee 28(6) 140-2
- Adverse Medicine Events Line 28(4) 102
- adverse reaction reporting 28(6) 140-2
 - dental notes 28(6) 142
- amiodarone in arrhythmia 28(6) 150-4
- anticonvulsants
 - in pregnancy and breastfeeding 31(3) 70-2
- antidepressants in pregnancy and breastfeeding 30(5) 125-7
 - letter 31(2) 32
- antipsychotic drugs
 - in pregnancy and breastfeeding 30(6) 162-3
- aspirin, alcohol and gastric bleeding 28(1) 18-9
 - letter 28(4) 84-7
- bisphosphonates and osteonecrosis of the jaw 30(4) 96-7
- bowel cleaning preparations 28(1) 16-7
- cabergoline-induced valvulopathy 31(1) 21
- cephalosporins and penicillin allergy 30(1) 25-6
- ciprofloxacin and fever (letter) 28(6) 136-9
- clindamycin and hepatotoxicity (medicinal mishap) 32(5) 140
- compatibilities of parenteral drug solutions 31(4) 98-101
 - letter 31(6) 143-5
- contrast media and 'iodine allergy' 32(5) 125-8
- corticosteroids
 - corticosteroid-induced osteoporosis and fractures 31(2) 45-9
- cough and cold remedies in children 32(5) 122-4
- cross-reactivity of penicillins and cephalosporins 30(1) 25-6
- digoxin - brands and dosages 29(6) 153
 - letter 30(2) 32-4
- drugs and road safety 31(2) 33-5
- ear drops and ototoxicity 31(2) 40-1
- fenofibrate-warfarin interactions 29(6) 166
 - letter 30(2) 32-4
- gingival bleeding 29(6) 154-5
- headache and analgesic overuse 28(6) 143-5
 - letter 29(3) 59-62
- hypnotics 31(6) 146-9
- hyponatraemia
 - with mirtazapine 31(4) 97
 - with omeprazole 28(2) 48-9
- inadequate consumer drug information sheets (letter) 31(6) 143-5
- interstitial nephritis with omeprazole 30(3) 67
- intravenous potassium chloride 28(1) 14-6
 - letters 28(4) 84-7
- isotretinoin in acne 28(3) 59-61
- label confusion between Atropt and Azopt (medicinal mishap) 32(5) 138
- metformin in pregnancy and lactation 30(3) 68-9
- metronidazole and breastfeeding (letter) 28(2) 29-33
- mirtazapine-induced hyponatraemia (medicinal mishap) 31(4) 97
 - letter 32(1) 5
- morphine dosages in acute pain (medicinal mishap) 32(1) 13
- muscle symptoms with simvastatin 28(4) 102
- neurocognitive effects of chemotherapy 31(1) 22-4
- neutropenia with quetiapine 31(1) 10-1
- NSAIDs and cardiovascular disease in rheumatology (editorial) 29(4) 90-1
- omeprazole and hyponatraemia 28(2) 48-9
- omeprazole and interstitial nephritis 30(3) 67
- online reporting 28(6) 140-2
- osteonecrosis of the jaw with bisphosphonates 30(4) 96-7
- overdoses of over-the-counter Donnalix Infant Drops 29(3) 83

- paracetamol, gastrointestinal bleeding and hypertension (letter) 30(3) 59-63
- pitfalls of prescribing generic drugs (letter) 28(4) 84-7
- polypharmacy (editorial) 31(1) 2-3
- salmeterol (editorial) 29(5) 118-9
- serotonin syndrome
 - - over-the-counter dextromethorphan 29(3) 71
 - - - letter 29(6) 149-50
- simvastatin and muscle symptoms 28(4) 102
 - - letter 28(6) 136-9
- starter packs and drug samples 30(1) 14-6
- sulfonamide allergy and cross-reactivity 31(1) 8-10
 - - letters 32(2) 31; 31(4) 88-9
- thiazolidinediones
 - - in diabetes (editorial) 31(3) 58-9
- toxicity with Donnalix Infant Drops 29(3) 83
- tramadol
 - - and hyponatraemia
 - - - letter 28(2) 29-33
- treatment of perinatal depression 31(2) 36-9
- tumour necrosis factor blockers - risk of malignancy (letter) 31(3) 60-2
- vascular effects of COX-2 selective inhibitors
 - - letters 28(2) 29-33
- xerostomia, drugs and radiotherapy 29(4) 97-8
 - - dental notes 29(4) 108
 - - letters 30(1) 3-4
- Adverse Medicine Events Line**
 - consumer reporting of adverse drug reactions 28(4) 102
 - starter packs and adverse effects 30(1) 14-6
- advertising**
 - complementary medicines (letter) 30(6) 140-1
 - direct-to-consumer advertising
 - - in New Zealand 29(2) 30-2
 - drug marketing and the internet 32(1) 2-4
 - drug promotion and health professionals (letters) 31(3) 60-2
 - efficacy of Ginkgo biloba in tinnitus (letter) 30(2) 32-4
 - Medicines Australia - code of conduct breaches 32(6) 160-1; 31(6) 162-3; 30(6) 153-5; 29(6) 164-5; 29(1) 16-7
 - - vardenafil 30(6) 154
 - regulation of complementary medicines (editorial) 31(6) 142-3
- aged**
 - beta blockers in hypertension 30(1) 5-7
 - Pharmaceutical Benefits Scheme restrictions on analgesics (PBAC question)
 - - update 28(1) 13
 - polypharmacy (editorial) 31(1) 2-3

AIDS - see HIV/AIDS

alcohol

- aspirin and gastric bleeding 28(1) 18-9
 - - letter 28(4) 84-7
- lifestyle management of hypertension 31(6) 150-3

aldosterone

- abnormal laboratory results 30(6) 147-9

Aldurazyme

- see laronidase 30(3) 79-82

alemtuzumab

- chronic lymphocytic leukaemia - MabCampath (New drug) 29(6) 167-71

alglucosidase alfa

- Pompe disease - Myozyme (New drug) 31(3) 79-83

Alimta

- see pemetrexed disodium 28(1) 19-23

aliskiren

- in hypertension 32(5) 135-8
- pharmacology of renin inhibitors 32(5) 132-5

allergy

- contrast media, seafood and 'iodine allergy' 32(5) 125-8
- monoclonal antibodies 29(5) 130-3
- patient support organisations - Anaphylaxis Australia 32(5) 128
- penicillins and cephalosporins (medicinal mishap) 30(1) 25-6
- sulfonamide allergy and cross-reactivity 31(1) 8-10
 - - letters 31(4) 88-9

alpha fetoprotein

- biochemical tests for abnormalities in pregnancy 29(2) 48-52

alpha-1-antitrypsin deficiency

- chronic obstructive pulmonary disease (letter) 30(6) 140-1

alternative medicines - see complementary medicines

Alvesco

- see ciclesonide 28(4) 104-6

Alzheimer's disease and dementia

- donepezil (editorial) 28(6) 134-5
 - - letter 29(3) 59-62
- management 32(1) 9-12
- management of behavioural problems 28(3) 67-70
- mental status testing 28(1) 11-3
- patient support organisations 28(3) 72
- risperidone for behavioural disturbances (RADAR comment) 28(3) 71

aminoglycosides

- ear drops and ototoxicity 31(2) 40-1

amiodarone

- arrhythmia 28(6) 150-4

amlodipine

- with valsartan - hypertension - Exforge (New drug) 32(1) 22-7

amphetamines

- adverse effects 29(4) 109-11

anaemia

- blood transfusion guidelines 28(2) 45-7
- epoetin beta - recombinant erythropoietin - Neorecormon (New drug) 29(4) 112-5
- iron sucrose - haemodialysis - Venofer (New drug) 28(2) 49-51
 - - letter 28(4) 84-7
- management in chronic kidney disease 31(6) 154-8
- management of uraemic and iron deficiency anaemia in chronic kidney disease 32(5) 129-131
- methoxy polyethylene glycol-epoetin beta - chronic kidney disease - Mircera (New drug) 32(6) 165-171

anaemia, aplastic

- antithymocyte globulin - Thymocyte (New drug) 31(5) 136-9

anaemia, haemolytic

- eculizumab - paroxysmal nocturnal haemoglobinuria - Soliris (New drug) 32(4) 112-5

anaesthetics

- articaine with adrenaline - dental anaesthesia - Septanest, Deltazine, Bucanest (New drug) 28(1) 19-23
- managing painful paediatric procedures 29(4) 94-6
 - - dental notes 29(4) 108
 - - letters 29(6) 149-50
 - - sugammadex - reversal of neuromuscular blockade by rocuronium or vecuronium - Bridion (New drug) 32(3) 82-6

analgesia

- lumiracoxib - Prexige (New drug) 29(1) 25-7
- managing acute pain in opioid dependence 31(5) 133-5
- morphine dosages in acute pain (medicinal mishap) 32(1) 13
- paediatric analgesia 31(3) 63-5
 - - letters 31(6) 143-5
- perioperative
 - - letter 28(2) 29-33
- Pharmaceutical Benefits Scheme restrictions and the aged (PBAC question)
 - - update 28(1) 13
- pregabalin - neuropathic pain - Lyrica (New drug) 28(3) 75-9

analgesics (see also anti-inflammatory drugs)

- etoricoxib - Arcoxia (New drug) 32(5) 142-5
- headache and analgesic overuse 28(6) 143-5
 - - letter 29(3) 59-62
- lumiracoxib - Prexige (New drug) 29(1) 25-7

- methylnaltrexone bromide - opioid analgesic-induced constipation - Relistor (New drug) 32(1) 22-7
- Therapeutic Guidelines - book review 31(2) 39
- anaphylaxis**
- contrast media, seafood and 'iodine allergy' 32(5) 125-8
- patient support organisation 32(5) 128
- repeat prescriptions of adrenaline auto-injectors (PBAC question) 28(4) 90
- wallchart - Emergency management of anaphylaxis in the community 2007 30(5) 115
- anecortave**
- macular degeneration - Retaane (New drug) 29(2) 53-5
- angina (see also coronary disease)**
- ivabradine - Corolan (New drug) 30(2) 50-5
- angiogenesis inhibitors**
- in cancer - clinical applications 29(1) 13-5
- in cancer - pharmacology 29(1) 9-12
- erlotinib - non-small cell lung cancer - Tarceva (New drug) 29(2) 53-5
- renal cell cancer 29(6) 151-3
- sorafenib - renal cell cancer- Nexavar (New drug) 29(6) 167-71
- sunitinib - gastrointestinal stromal tumour, renal cell cancer - Sutent (New drug) 29(6) 167-71
- angiography**
- magnetic resonance imaging in neuroradiology 31(1) 18-20
- Angiomax**
- see bivalirudin 28(3) 75-9
- angiotensin converting enzyme inhibitors - see ACE inhibitors**
- angiotensin receptor antagonists**
- amlodipine with valsartan - Exforge (New drug) 32(1) 22-7
- olmesartan medoxomil - Olmetec (New drug) 30(3) 79-82
- valsartan with hydrochlorothiazide - Co-Diovan (New drug) 32(1) 22-7
- valsartan - Diovan (New drug) 32(1) 22-7
- anidulafungin**
- invasive candidiasis - Eraxis (New drug) 32(6) 165-171
- anti-inflammatory drugs (see also analgesics)**
- dental and oral pain, management 30(3) 77-9
- NSAIDs
- - and cardiovascular disease in rheumatology (editorial) 29(4) 90-1
- - in paediatric analgesia 31(3) 63-5
- anti-thymocyte globulin**
- kidney transplantation and aplastic anaemia - Thymoglobuline (New drug) 31(5) 136-9
- antiandrogens**
- triptorelin embonate - prostate cancer - Diphereline (New drug) 32(1) 22-7
- antiarrhythmic drugs - see arrhythmia**
- antibiotics**
- antibiotic guidelines and endocarditis
- - dental notes 31(6) 153
- in bronchiectasis 31(3) 77-9
- - letter 31(5) 115-8
- cephalosporins and penicillin allergy 30(1) 25-6
- clindamycin and hepatotoxicity (medicinal mishap) 32(5) 140
- cross-reactivity of penicillins and cephalosporins (medicinal mishap) 30(1) 25-6
- daptomycin - skin infections, Staphylococcus aureus bacteraemia - Cubicin (New drug) 32(2) 51-5
- dental and oral pain, management 30(3) 77-9
- doripenem - specified infections - Doribax (New drug) 32(3) 82-6
- ear drops and ototoxicity 31(2) 40-1
- foot infections in diabetes 30(1) 21-4
- management of animal and human bites 29(1) 6-8
- - letters 29(3) 59-62
- in management of pertussis in adults 32(2) 36-8
- otitis media management in children 32(6) 155-9
- resistance
- - community-acquired methicillin-resistant Staphylococcus aureus infection 28(6) 155
- - - letter 29(3) 59-62
- rifampicin and MRSA infections - Orphan Drug Scheme (letter) 29(1) 3-5
- sulfonamide allergy and cross-reactivity 31(1) 8-10
- - letters 32(2) 31; 31(4) 88-9
- surgical prophylaxis 28(2) 38-40
- - dental notes 28(2) 41
- - letters 28(5) 113-5; 28(3) 55-8
- Therapeutic Guidelines: Antibiotic - book reviews 30(3) 73
- tigecycline - complicated infections - Tygacil (New drug) 29(5) 138-43
- antibodies, monoclonal - see monoclonal antibodies**
- anticancer drugs - see antineoplastics**
- anticholinergic drugs**
- darifenacin hydrobromide - overactive bladder - Enablex (New drug) 29(5) 138-43
- overactive bladder 29(1) 22-4
- - letter 29(4) 91-3
- overdoses in infantile colic 29(3) 83
- solifenacin succinate - overactive bladder - Vesicare (New drug) 29(5) 138-43
- tolterodine - overactive bladder - Detrusitol (New drug) 28(2) 49-51
- toxicity with Donnalix Infant Drops (medicinal mishap) 29(3) 83
- anticholinesterase - see cholinesterase inhibitors**
- anticoagulants**
- bivalirudin - percutaneous coronary intervention - Angiomax (New drug) 28(3) 75-9
- dabigatran etexilate - prevention of postoperative venous thrombosis - Pradaxa (New drug) 32(2) 51-5
- gingival bleeding 29(6) 154-5
- heparins in venous thromboembolism prophylaxis 32(4) 108-12
- human protein C - Ceprotin - congenital protein C deficiency (New drug) 30(2) 50-5
- rivaroxaban - prevention of postoperative venous thrombosis - Xarelto (New drug) 32(1) 22-7
- warfarin
- - bioequivalence of Marevan and Coumadin
- - - letters 30(2) 32-4
- - interactions with fenofibrate 29(6) 166
- - - letter 30(2) 32-4
- - pharmacogenetic testing 32(3) 76-80
- - - dental notes 32(3) 80
- - - letter 32(5) 119-121
- anticonvulsants (see also epilepsy)**
- in bipolar disorders 30(3) 70-3
- management of behavioural problems in dementia 28(3) 67-70
- in neuropathic pain 29(3) 72-5
- pregabalin - Lyrica (New drug) 28(3) 75-9
- in pregnancy and breastfeeding 31(3) 70-2
- withdrawal of drugs in seizure-free children 29(1) 18-21
- antidepressant drugs**
- acute management of bipolar disorders 31(3) 73-6
- - letter 31(5) 115-8
- depression in medical illness 30(4) 86-8
- desvenlafaxine - Pristiq (New drug) 32(1) 22-7
- duloxetine - major depression - Cymbalta (New drug) 31(3) 79-83
- management of behavioural problems in dementia 28(3) 67-70
- management of mild depression in general practice 28(1) 8-10
- mirtazapine-induced hyponatraemia (medicinal mishap) 31(4) 97
- - letter 32(1) 5
- neuropathic pain 29(3) 72-5
- pregnancy and breastfeeding 30(5) 125-7
- - letter 31(2) 32
- psychotropic drugs for children in general practice 28(5) 116-8
- suicide risk in children (editorials) 28(5) 110-1; 28(5) 111-3
- - letter 29(2) 32-5

- treatment of non-depressive disorders 28(4) 91-3
- treatment of perinatal depression 31(2) 36-9
- antiemetics**
- aprepitant
- - in cancer chemotherapy (PBAC question) 28(5) 119
- antiepileptics - see anticonvulsants**
- antifungal drugs**
- anidulafungin - invasive candidiasis - Eraxis (New drug) 32(6) 165-171
- butoconazole nitrate - candidal vulvovaginitis - Gynazole (New drug) 29(5) 138-43
- posaconazole - Noxafil (New drug) 29(3) 84-7
- antihistamines - see histamine**
- antihypertensives**
- beta blockers 30(1) 5-7
- - letter 30(3) 59-63
- eplerenone - heart failure post-myocardial infarction - Inspra (New drug) 28(5) 130-1
- - letter 29(2) 32-5
- management of uncomplicated hypertension 28(2) 34-7
- - letter 28(5) 113-5
- moxonidine - Physiotens (New drug) 29(1) 25-7
- olmesartan medoxomil - Olmetec (New drug) 30(3) 79-82
- pharmacology of renin inhibitors 32(5) 132-5
- renin inhibitors 32(5) 135-8
- valsartan with hydrochlorothiazide - Co-Diovan (New drug) 32(1) 22-7
- valsartan - Diovan (New drug) 32(1) 22-7
- antileukotriene drugs - see leukotriene receptor antagonists**
- antilipidaemic drugs**
- fenofibrate
- - interactions with warfarin 29(6) 166
- - - letter 30(2) 32-4
- management of hypercholesterolaemia 31(5) 119-22
- and muscle symptoms 28(4) 102
- - letter 28(6) 136-9
- rosuvastatin - hypercholesterolaemia - Crestor (New drug) 29(6) 167-71
- antimalarials - see malaria**
- antineoplastics**
- alemtuzumab - MabCampath - chronic lymphocytic leukaemia (New drug) 29(6) 167-71
- angiogenesis inhibitors in cancer 29(1) 9-12; 29(1) 13-5
- aprepitant
- - as antiemetic in cancer chemotherapy (PBAC question) 28(5) 119
- arsenic trioxide - acute promyelocytic leukaemia - Phenasen (New drug) 32(5) 142-5
- bevacizumab - colorectal cancer - Avastin (New drug) 28(4) 104-6
- bortezomib - multiple myeloma - Velcade (New drug) 29(3) 84-7
- cetuximab - colorectal cancer - Erbitux (New drug) 28(4) 104-6
- chemotherapy and cancer survival rates (editorial) 29(1) 2-3
- dasatinib - Sprycel - chronic myeloid and acute lymphoblastic leukaemia (New drug) 30(2) 50-5
- erlotinib - Tarceva - non-small cell lung cancer (New drug) 29(2) 53-5
- fosaprepitant - Emend IV - emetogenic cancer chemotherapy (New drug) 31(4) 108-11
- fulvestrant - breast cancer - Faslodex (New drug) 30(4) 107-11
- lapatinib - breast cancer - Tykerb (New drug) 30(5) 133-5
- lenalidomide - multiple myeloma - Revlimid (New drug) 31(2) 49-55
- leukaemia in adults 29(3) 76-9
- neurocognitive effects of chemotherapy 31(1) 22-4
- nilotinib - chronic myeloid leukaemia - Tassigna (New drug) 31(2) 49-55
- palifermin - Kepivance - oral mucositis prevention in chemotherapy (New drug) 28(6) 156-8
- pancreatic carcinoma 28(2) 42-4
- panitumumab - Vectibix - metastatic colorectal cancer (New drug) 31(5) 136-9
- pemetrexed disodium - lung cancer, mesothelioma - Alimta (New drug) 28(1) 19-23
- renal cell cancer 29(6) 151-3
- sorafenib - Nexavar - renal cell cancer (New drug) 29(6) 167-71
- sunitinib - Sutent - gastrointestinal stromal tumour, renal cell cancer (New drug) 29(6) 167-71
- taxanes and breast cancer (PBAC question) 30(1) 24-5
- temsirolimus - Torisel - renal cell carcinoma (New drug) 31(4) 108-11
- antipsychotics**
- in bipolar disorders 30(3) 70-3
- long-term community management of psychotic disorders 30(2) 44-6
- management of behavioural problems in dementia 28(3) 67-70
- neutropenia with quetiapine (medicinal mishap) 31(1) 10-1
- paliperidone - schizophrenia - Invega (New drug) 31(2) 49-55
- in pregnancy and breastfeeding 30(6) 162-3
- ziprasidone - Zeldox (New drug) 30(2) 50-5
- - letter 30(3) 59-63
- antiretroviral drugs (see also antiviral drugs)**
- darunavir - HIV - Prezista (New drug) 30(3) 79-82
- emtricitabine - HIV - Emtriva (New drug) 28(2) 49-51
- etravirine - HIV - Intelence (New drug) 32(2) 51-5
- HIV fusion inhibitors - pharmacology 31(3) 66-9
- HIV infection 28(6) 146-9
- maraviroc - HIV - Celsentri (New drug) 31(6) 165-7
- raltegravir - HIV - Isentress (New drug) 31(2) 49-55
- tipranavir - HIV - Aptivus (New drug) 30(4) 107-11
- antivenoms**
- management of injuries by sea creatures 30(5) 117-21
- - letter 31(2) 32
- snake bites 29(5) 125-9
- spider bites 29(6) 156-8
- antiviral drugs (see also antiretroviral drugs)**
- entecavir - chronic hepatitis B - Baraclude (New drug) 29(5) 138-43
- etravirine - HIV - Intelence (New drug) 32(2) 51-5
- hepatitis B 32(4) 99-104
- hepatitis C 29(2) 36-9
- influenza prophylaxis (editorial) 30(2) 30-1
- telbivudine - chronic hepatitis B - Sebivo (New drug) 30(6) 163-7
- anxiety disorders**
- treatment with antidepressants 28(4) 91-3
- Apidra SoloStar**
- see insulin glulisine 30(5) 133-5
- APMA - see Australian Pharmaceutical Manufacturers Association**
- aprepitant**
- antiemetic in cancer chemotherapy (PBAC question) 28(5) 119
- Aptivus**
- see tipranavir 30(4) 107-11
- arachnidism**
- management 29(6) 156-8
- Arcoxia**
- see etoricoxib 32(5) 142-5
- arrhythmia (see also atrial fibrillation)**
- amiodarone 28(6) 150-4
- arsenic trioxide**
- acute promyelocytic leukaemia - Phenasen (New drug) 32(5) 142-5
- arthritis (see also osteoarthritis; rheumatology)**
- NSAIDs and cardiovascular disease (editorial) 29(4) 90-1
- rheumatoid
- - abatacept - Orencia (New drug) 30(6) 163-7

- - abnormal laboratory results - antibodies to cyclic citrullinated peptides 29(6) 162-4
- - tumour necrosis factor blockers 29(3) 67-70

- - - letter 28(1) 5-7

- - - risk of malignancy (letter) 31(3) 60-2

articaine with adrenaline

- Septanest, Deltazine, Bucanest - dental anaesthesia (New drug) 28(1) 19-23
- - correction 28(2) 49-51

aspirin

- alcohol and gastric bleeding 28(1) 18-9
- - letter 28(4) 84-7
- antiplatelet therapy after coronary stents 30(4) 92-6

asthma

- ciclesonide - asthma prophylaxis - Alvesco (New drug) 28(4) 104-6
- combination inhalers 28(2) 26-8
- salmeterol - safety concerns (editorial) 29(5) 118-9
- starting corticosteroid therapy 29(3) 63-6

atenolol

- beta blockers in hypertension 30(1) 5-7
- - letter 30(3) 59-63

atomoxetine

- in attention deficit hyperactivity disorder 31(5) 129-32

atropine

- label confusion between Atropt and Azopt (medicinal mishap) 32(5) 138

Atropt

- see atropine 32(5) 138

attention deficit hyperactivity disorder

- management 31(5) 129-32
- methylphenidate (PBAC questions) 31(3) 76
- psychotropic drugs for children in general practice 28(5) 116-8

AusPharm Consumer Health Watch

- publishing of drug evaluations (editorial) 29(5) 120
- - letter 30(2) 32-4

Australian Medicines Handbook

- book reviews 28(4) 93; 28(2) 41

Australian Prescriber

- 30th anniversary and history 28(5) 120-2
- - letter 29(2) 32-5
- declarations of conflict of interest (letter) 29(4) 91-3
- Editorial Executive Committee - chairman - valedication 28(5) 115
- information from the drug industry about new drugs 28(4) 103
- - letter 29(3) 59-62
- transparency of new drug information 32(3) 80-1; 30(1) 26-7; 28(4) 103
- website user surveys 30(1) 16

autoimmune diseases

- antibodies to cyclic citrullinated peptides in rheumatoid arthritis 29(6) 162-4
- immunosuppressants 29(4) 102-8

- long-term management of patients taking immunosuppressants 32(3) 68-71

- - dental notes 32(3) 75

- monoclonal antibodies 29(5) 130-3

- myasthenia gravis 30(6) 156-60

Avastin

- see bevacizumab 28(4) 104-6

avian influenza

- antiviral drugs and vaccination (editorial) 30(2) 30-1

aviation - see travel

Avodart

- see dutasteride 32(4) 112-5

azathioprine

- in myasthenia gravis 30(6) 156-60
- pharmacology of immunosuppressants 29(4) 99-101

Azopt

- see brinzolamide 32(5) 138

B

bacteraemia

- daptomycin - Staphylococcus aureus bacteraemia - Cubicin (New drug) 32(2) 51-5

balsalazide

- ulcerative colitis - Colazide (New drug) 28(4) 104-6
- - letter 29(2) 32-5

Baraclude

- see entecavir 29(5) 138-43

beclomethasone dipropionate

- corticosteroid therapy in asthma 29(3) 63-6

behaviour disorders

- attention deficit hyperactivity disorder
- - management 31(5) 129-32
- - methylphenidate (PBAC question) 31(3) 76
- management of dementia 28(3) 67-70
- psychotropic drugs for children in general practice 28(5) 116-8
- risperidone in dementia (RADAR comment) 28(3) 71

Bence-Jones protein

- multiple myeloma screening 32(4) 92-4

benzodiazepines

- drugs and road safety 31(2) 33-5
- in insomnia
- - comparisons with zolpidem and zopiclone 31(6) 146-9

beta agonists

- corticosteroid combination inhalers in asthma 28(2) 26-8
- salmeterol - safety concerns (editorial) 29(5) 118-9

beta blockers

- hypertension 30(1) 5-7
- - letter 30(3) 59-63

bevacizumab

- angiogenesis inhibitors in cancer 29(1) 9-12; 29(1) 13-5

- colorectal cancer - Avastin (New drug)

28(4) 104-6

- in renal cell cancer 29(6) 151-3

bioavailability

- meals and medicines 29(2) 40-2

bioequivalence

- biosimilars are not (bio)generics (editorial) 32(6) 146-7

- generic drugs 30(2) 41-3

- - letter 30(4) 88-90

- Marevan and Coumadin (letter) 30(2) 32-4

- prescription drug pricing 32(1) 6-8

biological products (see also monoclonal antibodies and specific drugs)

- bioequivalence of biosimilars (editorial) 32(6) 146-7

bipolar disorders

- acute management 31(3) 73-6
- - letter 31(5) 115-8
- bipolar I - ziprasidone - Zeldox (New drug) 30(2) 50-5
- - letter 30(3) 59-63
- drug therapy 30(3) 70-3

birth defects

- anticonvulsants in pregnancy and breastfeeding 31(3) 70-2
- antidepressants in pregnancy 30(5) 125-7
- - letter 31(2) 32
- biochemical tests in pregnancy 29(2) 48-52
- isotretinoin in acne 28(3) 59-61
- metformin in pregnancy and lactation 30(3) 68-9

bisphosphonates

- ibandronic acid - hypercalcaemia, bony metastases of breast cancer - Bondronat (New drug) 31(3) 79-83
- and osteonecrosis of the jaws 30(4) 96-7
- prevention of corticosteroid-induced bone loss 31(2) 45-9

bites and stings

- management of animal and human bites 29(1) 6-8
- - letters 29(3) 59-62
- sea creatures 30(5) 117-21
- - letter 31(2) 32
- snake bites 29(5) 125-9
- spider bites 29(6) 156-8

bivalirudin

- percutaneous coronary intervention - Angiomax (New drug) 28(3) 75-9

bladder, overactive

- anticholinergic drugs 29(1) 22-4
- - letter 29(4) 91-3
- darifenacin hydrobromide - Enablex (New drug) 29(5) 138-43
- solifenacin succinate - Vesicare - (New drug) 29(5) 138-43
- tolterodine - Detrusitol (New drug) 28(2) 49-51

blood coagulation factors

- factor VIII inhibitor bypassing fraction - haemophilia - FEIBA-NF (New drug) 30(2) 50-5

blood pressure - see antihypertensives; hypertension

blood transfusion

- guidelines 28(2) 45-7

blood volume

- pentastarch - hypovolaemia - Voluven (New drug) 30(4) 107-11

Bondronat

- see ibandronic acid 31(3) 79-83

bone fractures

- corticosteroid-induced 31(2) 45-9

Bordetella pertussis infection - see pertussis

bortezomib

- multiple myeloma - Velcade (New drug) 29(3) 84-7

- new drugs for multiple myeloma 32(4) 95-8

botulinum toxin

- clinical use 32(2) 39-42

bowel

- preparation 28(1) 16-7

brain

- magnetic resonance imaging in neuroradiology 31(1) 18-20

breast cancer

- fulvestrant - Faslodex (New drug) 30(4) 107-11

- ibandronic acid - hypercalcaemia, bony metastases of breast cancer - Bondronat (New drug) 31(3) 79-83

- lapatinib - Tykerb (New drug) 30(5) 133-5

- taxanes (PBAC question) 30(1) 24-5

breastfeeding

- anticonvulsants 31(3) 70-2

- antidepressants 30(5) 125-7

- - letter 31(2) 32

- antipsychotics 30(6) 162-3

- Drugs and breastfeeding (book review)

- - metronidazole (letter) 28(2) 29-33

- metformin and diabetes 30(3) 68-9

- treatment of perinatal depression 31(2) 36-9

Bridion

- see sugammadex 32(3) 82-6

brinzolamide

- label confusion between Atropt and Azopt (medicinal mishap) 32(5) 138

bronchiectasis

- management 31(3) 77-9

- - letter 31(5) 115-8

bronchodilators

- in chronic obstructive pulmonary disease 30(3) 64-7

- - letter - alpha-1-antitrypsin deficiency 30(6) 140-1

bruxism

- psychotropic drugs and dentistry 30(4) 98-101

Bucanest

- see articaine 28(1) 19-23

budesonide

- combination inhalers in asthma 28(2) 26-8

- corticosteroid therapy in asthma 29(3) 63-6

butoconazole nitrate

- candidal vulvovaginitis - Gynazole (New drug) 29(5) 138-43

Byetta

- see exenatide 30(6) 163-7

C

C-reactive protein

- abnormal laboratory results 30(3) 74-6

cabergoline

- cabergoline-induced valvulopathy (medicinal mishap) 31(1) 21

caesarian section

- carbetocin - prevention of uterine atony - Duratocin (New drug) 30(4) 107-11

calcineurin inhibitors

- management of patients taking immunosuppressants 32(3) 68-71

- pharmacology of immunosuppressants 29(4) 99-101; 29(4) 102-8

calcium supplementation

- prevention of corticosteroid-induced bone loss 31(2) 45-9

cancer (see also antineoplastics and specific organs)

- angiogenesis inhibitors - pharmacology 29(1) 9-12; 29(1) 13-5

- chemotherapy and cancer survival rates (editorial) 29(1) 2-3

- neurocognitive effects of chemotherapy 31(1) 22-4

- oral mucositis prevention in chemotherapy - palifermin - Kepivance (New drug) 28(6) 156-8

- positron emission tomography 31(5) 123-8

- radiotherapy and xerostomia 29(4) 97-8

- - dental notes 29(4) 108

- - letters 30(1) 3-4

- tumour necrosis factor blockers - risk of malignancy (letter) 31(3) 60-2

- tumour-induced hypercalcaemia - ibandronic acid - Bondronat (New drug) 31(3) 79-83

cancer chemotherapy - see antineoplastics

candidiasis

- anidulafungin - invasive candidiasis - Eraxis (New drug) 32(6) 165-171

- butoconazole nitrate - candidal vulvovaginitis - Gynazole (New drug) 29(5) 138-43

carbamazepine

- in bipolar disorders 30(3) 70-3

carbapenem antibiotics

- doripenem - specified infections - Doribax (New drug) 32(3) 82-6

carbetocin

- prevention of uterine atony after caesarian section - Duratocin (New drug) 30(4) 107-11

carcinoma, renal cell - see renal cell carcinoma

cardiovascular diseases

- antiretroviral therapy in HIV infection 28(6) 146-9

- diabetes

- - exercise 30(5) 130-3

- - glucose control (editorial) 32(2) 30-1

- echocardiography 29(5) 134-8

- - letter 30(1) 3-4

- endocarditis - dental notes 31(6) 153

- hypertension management 31(6) 150-3

- managing risk in chronic kidney disease 31(6) 154-8

- NSAIDs in rheumatology (editorial) 29(4) 90-1

- the polypill controversy (editorial) 28(4) 82-3

- Therapeutic Guidelines - book reviews 31(6) 158

- thiazolidinedione adverse effects in diabetes (editorial) 31(3) 58-9

- undertreatment in rural populations (editorial) 31(4) 86-7

celecoxib

- vascular effects of COX-2 selective inhibitors

- - letter 28(2) 29-33

cell markers

- abnormal laboratory results 30(5) 128-9

Celsentri

- see maraviroc 31(6) 165-7

cephalosporins

- penicillin allergy 30(1) 25-6

Ceprotrin

- see protein C 30(2) 50-5

cerebrovascular disorders

- beta blockers in hypertension 30(1) 5-7

- - letter 30(3) 59-63

- magnetic resonance imaging in neuroradiology 31(1) 18-20

Certican

- see everolimus 28(3) 75-9

Cervarix

- human papillomavirus vaccine 30(5) 133-5

cervical cancer

- human papillomavirus vaccine - Cervarix (New drug) 30(5) 133-5

- human papillomavirus vaccine - Gardasil (New drug) 29(5) 138-43

cetuximab

- colorectal cancer - Erbitux (New drug) 28(4) 104-6

Champix

- see varenicline 31(5) 115-8; 31(3) 60-2; 31(1) 24-7

chelating agents

- deferasirox - iron overload - Exjade (New drug) 29(4) 112-5

chemotherapy, cancer - see antineoplastics**chest X-rays**

- thoracic computed tomography 32(4) 105-7

chickenpox

- varicella vaccine - frequently asked questions 28(1) 2-5
- - letters 28(5) 113-5; 28(3) 55-8

children (see also infants; attention deficit hyperactivity disorder)

- abnormal laboratory results - paediatric biochemical tests 28(5) 126-9
- antidepressants and suicide risk (editorials) 28(5) 110-1; 28(5) 111-3
- - letter 29(2) 32-5
- cough and cold remedies 32(5) 122-4
- diagnosis and management of vulvovaginitis 28(4) 88-90
- Drugs and breastfeeding (book review)
- - metronidazole (letter) 28(2) 29-33
- management of attention deficit hyperactivity disorder 31(5) 129-32
- managing painful paediatric procedures 29(4) 94-6
- - dental notes 29(4) 108
- - letters 29(6) 149-50
- motion sickness prevention 32(3) 61-3
- otitis media management 32(6) 155-9
- overdoses of over-the-counter drugs in infantile colic 29(3) 83
- over-the-counter medications
- - overdoses of anticholinergic drugs in infantile colic 29(3) 83
- paediatric analgesia 31(3) 63-5
- - letters 31(6) 143-5
- psychotropic drugs for children in general practice 28(5) 116-8
- rotavirus vaccine - Rotarix (New drug) 29(4) 112-5
- rotavirus vaccine - RotaTeq (New drug) 29(4) 112-5
- withdrawal of antiepileptic drugs from seizure-free children 29(1) 18-21

chiral drugs

- pharmacology and efficacy
- - correction 28(3) 55-8

chlamydia

- abnormal laboratory results 30(1) 8-13

chlorpromazine

- in pregnancy and breastfeeding 30(6) 162-3

cholinesterase inhibitors

- dementia 32(1) 9-12

chronic obstructive pulmonary disease - see pulmonary disease**ciclesonide**

- asthma prophylaxis - Alvesco (New drug) 28(4) 104-6
- corticosteroid therapy in asthma 29(3) 63-6

cilostazol

- intermittent claudication - Pletal (New drug) 32(3) 82-6

cinacalcet

- hyperparathyroidism, hypercalcaemia - Sensipar (New drug) 28(3) 75-9

ciprofloxacin

- and fever (letter) 28(6) 136-9

citalopram

- serotonin syndrome (medicinal mishap) 29(3) 71

climate change

- and infectious diseases (editorial) 32(3) 58-9

clindamycin

- hepatotoxicity (medicinal mishap) 32(5) 140

clinical pharmacology - see pharmacology**clinical tests - see abnormal laboratory results; diagnostic tests****clinical trials**

- appraising medical research 29(5) 122-4
- development of new prescription drugs 29(6) 159-61
- interpreting risks and ratios 31(1) 12-6
- pharmacotherapy for risk factors 30(2) 47-50
- risk factor pharmacotherapy (letter) 30(4) 88-90
- surrogate outcome markers 32(2) 47-50

clopidogrel

- antiplatelet therapy after coronary stents 30(4) 92-6

CMI - see Consumer Medicine Information**Co-Diovan**

- see valsartan with hydrochlorothiazide 32(1) 22-7

cocaine

- adverse effects 29(4) 109-11

codeine

- paediatric analgesia 31(3) 63-5

cognition

- neurocognitive effects of chemotherapy 31(1) 22-4

cognitive behaviour therapy

- depression in medical illness 30(4) 86-8
- management of mild depression in general practice 28(1) 8-10
- treatment of non-depressive disorders 28(4) 91-3

cognitive testing

- mental status testing in dementia 28(1) 11-3

Colazide

- see balsalazide 29(2) 32-5; 28(4) 104-6

colic, infantile

- overdoses of over-the-counter anticholinergic drugs 29(3) 83

colitis, ulcerative

- balsalazide - Colazide (New drug) 28(4) 104-6
- - letter 29(2) 32-5

colonic diseases

- bowel preparation 28(1) 16-7

colonoscopy

- bowel preparation 28(1) 16-7

colorectal cancer

- angiogenesis inhibitors 29(1) 13-5
- bevacizumab - Avastin (New drug) 28(4) 104-6
- cetuximab - Erbitux (New drug) 28(4) 104-6
- panitumumab - Vectibix (New drug) 31(5) 136-9

combination products

- the polypill and cardiovascular disease (editorial) 28(4) 82-3

complement inhibitors

- eculizumab - paroxysmal nocturnal haemoglobinuria - Soliris (New drug) 32(4) 112-5

complementary medicines

- 1907 Royal Commission on Secret Drugs, Cures and Foods 30(4) 91
- - letter 30(6) 140-1
- efficacy of Ginkgo biloba in tinnitus (editorial) 29(5) 120
- - letter 30(2) 32-4
- regulation of advertising (editorial) 31(6) 142-3

compliance - see patient compliance**computed tomography**

- magnetic resonance imaging in neuroradiology 31(1) 18-20
- thoracic 32(4) 105-7

computerised prescribing systems - see electronic prescribing**confidence intervals**

- interpreting risks and ratios 31(1) 12-6

congenital abnormalities - see birth defects**congestive heart failure - see heart failure, congestive****conjunctivitis**

- ketotifen - seasonal allergic conjunctivitis - Zaditen (New drug) 28(1) 19-23

Conn's syndrome

- abnormal laboratory results 30(6) 147-9

constipation

- methylnaltrexone bromide - opioid-induced constipation - Relistor (New drug) 32(1) 22-7

consumer - see consumers; patient**consumer information (see also Consumer Medicine Information)**

- Aboriginal patients 28(5) 123-5
- Adverse Medicine Events Line 28(4) 102
- aspirin and alcohol 28(1) 18-9
- - letter 28(4) 84-7
- drug labelling and packaging (letter) 28(1) 5-7
- - letter 28(4) 84-7
- Media Doctor 28(1) 13
- overseas travel and medicines 29(3) 80-2
- pharmacotherapy for risk factors 30(2) 47-50

- publishing of drug evaluations (editorial) 29(5) 120
- - letter 30(2) 32-4
- quality use of generic drugs (editorial)
- - letters 28(2) 29-33
- starter packs and drug samples 30(1) 14-6
- Consumer Medicine Information**
- inadequate drug information sheets (letter) 31(6) 143-5
- letter 31(2) 32
- utilisation 30(5) 122-4
- consumers (see also patient's perspective)**
- direct drug advertising
- - in New Zealand (editorial) 29(2) 30-2
- Continence Foundation of Australia**
- patient support organisation 29(1) 24
- contraceptives**
- dienogest/ethinylloestradiol - Valette (New drug) 30(2) 50-5
- overseas travel and medicines 29(3) 80-2
- in polycystic ovary syndrome
- - letter 28(3) 55-8
- thromboembolism
- - prophylaxis and flying 32(6) 148-50
- contrast media**
- disodium gadoxetate - liver imaging - Primovist (New drug) 29(3) 84-7
- 'iodine allergy' 32(5) 125-8
- perflutren - ultrasound - Definity (New drug) 30(4) 107-11
- COPD - see pulmonary disease, chronic obstructive**
- Corolan**
- see ivabradine 30(2) 50-5
- coronary disease (see also angina; myocardial infarction)**
- antiplatelet therapy after coronary stents 30(4) 92-6
- management of hypercholesterolaemia 31(5) 119-22
- coronary intervention, percutaneous**
- antiplatelet therapy after coronary stents 30(4) 92-6
- bivalirudin - anticoagulant - Angiomax (New drug) 28(3) 75-9
- corticosteroids**
- in asthma 29(3) 63-6
- beta agonist combination inhalers in asthma 28(2) 26-8
- in bronchiectasis 31(3) 77-9
- - letter 31(5) 115-8
- in chronic obstructive pulmonary disease 30(3) 64-7
- - letter - alpha-1-antitrypsin deficiency 30(6) 140-1
- ciclesonide - asthma prophylaxis - Alvesco (New drug) 28(4) 104-6
- management of patients taking immunosuppressants 32(3) 68-71
- osteoporosis and fractures 31(2) 45-9
- pharmacology of immunosuppressants 29(4) 102-8

- cortisol**
- abnormal laboratory results 30(6) 147-9
- cost of drugs**
- drug price reforms (editorial) 30(6) 138-40
- funding of influenza vaccination for healthy adults 30(2) 35-7
- - letter 30(5) 116
- prescription drug pricing 32(1) 6-8
- - letter 32(3) 60
- top 10 drugs 32(6) 159; 31(6) 164; 30(6) 142; 29(6) 167; 29(1) 5; 28(2) 37
- US Medicare program (editorial) 32(4) 90-1
- cost-effectiveness of drugs**
- expensive drugs and the Pharmaceutical Benefits Scheme (editorial) 29(6) 146-8
- - letter 30(3) 59-63
- expensive new drugs (editorials)
- - letter 28(3) 55-8
- counselling**
- management of mild depression in general practice 28(1) 8-10
- COX inhibitors**
- etoricoxib - analgesia, gout, osteoarthritis - Arcoxia (New drug) 32(5) 142-5
- lumiracoxib - Prexige (New drug) 29(1) 25-7
- safety of new drugs (editorial) 28(3) 54-5
- vascular effects of COX-2 selective inhibitors
- - letters 28(2) 29-33; 28(2) 29-33; 28(2) 29-33
- cramp**
- magnesium (letter) 30(6) 140-1
- creatinine clearance**
- drug dosage adjustment in kidney disease 30(1) 17-20
- - letter 30(2) 32-4
- Crestor**
- see rosuvastatin 29(6) 167-71
- CT - see computed tomography**
- Cubicin**
- see daptomycin 32(2) 51-5
- Curosurf**
- see poractant alfa 28(3) 75-9
- Cushing's syndrome**
- abnormal laboratory results 30(6) 147-9
- mifepristone 32(6) 152-4
- cyclo-oxygenase inhibitors - see COX inhibitors**
- cyclosporin**
- pharmacology of immunosuppressants 29(4) 99-101
- Cymbalta**
- see duloxetine 31(3) 79-83
- cystic fibrosis**
- management of bronchiectasis 31(3) 77-9
- - letter 31(5) 115-8
- cytochrome P450**
- warfarin pharmacogenetic testing 32(3) 76-80
- - letter 32(5) 119-121

cytotoxic drugs - see antineoplastics

D

- dabigatran etexilate**
- prevention of postoperative venous thrombosis - Pradaxa (New drug) 32(2) 51-5
- dalteparin**
- heparins in venous thromboembolism prophylaxis 32(4) 108-12
- danaparoid**
- heparins in venous thromboembolism prophylaxis 32(4) 108-12
- daptomycin**
- skin infections, Staphylococcus aureus bacteraemia - Cubicin (New drug) 32(2) 51-5
- darbepoetin alfa**
- management of anaemia in chronic kidney disease 32(5) 129-131
- darifenacin hydrobromide**
- overactive bladder - Enablex (New drug) 29(5) 138-43
- darunavir**
- HIV infection - Prezista (New drug) 30(3) 79-82
- dasatinib**
- chronic myeloid and acute lymphoblastic leukaemia - Sprycel (New drug) 30(2) 50-5
- decision-support software - see electronic prescribing**
- deep venous thrombosis - see thromboembolism**
- deferasirox**
- iron overload - Exjade (New drug) 29(4) 112-5
- Definity**
- see perflutren 30(4) 107-11
- Deltazine**
- see articaine 28(1) 19-23
- dementia - see Alzheimer's disease and dementia**
- dental anaesthesia**
- articaine with adrenaline - Septanest, Deltazine, Bucanest (New drug) 28(1) 19-23
- dental hygiene**
- for adults 32(3) 72-5
- mouthwashes 32(6) 162-4
- dental implications - see dental notes**
- dental notes**
- adverse reaction reporting 28(6) 142
- antibiotics for surgical prophylaxis 28(2) 41
- - letters 28(5) 113-5; 28(3) 55-8
- antiretroviral therapy in HIV infection 28(6) 149
- bioequivalence of generic drugs 30(2) 43
- drug promotion and dentistry 30(6) 153
- emergency drugs in dentistry 30(6) 146

- herpes simplex infections 30(1) 13
- infective endocarditis prophylaxis 31(6) 153
- influenza vaccination for healthy adults 30(2) 37
- management of hepatitis C 29(2) 52
 - - letter 30(3) 59-63
- management of patients taking immunosuppressants 32(3) 75
- managing acute pain in opioid dependence 31(5) 133-5
- managing painful paediatric procedures 29(4) 108
- myasthenia gravis 30(6) 160
- neuropathic pain, drug treatment 29(3) 82
- psoriasis and periodontal disease 32(1) 18
- warfarin pharmacogenetic testing 32(3) 80
- xerostomia 29(4) 108
- dental pain**
 - management 30(3) 77-9
 - managing acute pain in opioid dependence 31(5) 133-5
- dental plaque**
 - dental hygiene for adults 32(3) 72-5
- dentistry**
 - bisphosphonates
 - - and osteonecrosis of the jaws 30(4) 96-7
 - dizziness and prolonged dental treatment (letter) 28(6) 136-9
 - drugs and gingival bleeding 29(6) 154-5
 - echocardiography and endocarditis (letter) 30(1) 3-4
 - mouthwashes 32(6) 162-4
 - and psychotropic drugs 30(4) 98-101
 - Therapeutic Guidelines - Oral and Dental (book review) 30(4) 106
- depression (see also antidepressant drugs)**
 - antidepressants and suicide risk in children (editorials) 28(5) 110-1; 28(5) 111-3
 - - letter 29(2) 32-5
 - antidepressants in pregnancy and breastfeeding 30(5) 125-7
 - - letter 31(2) 32
 - duloxetine - major depression - Cymbalta (New drug) 31(3) 79-83
 - management of mild depression in general practice 28(1) 8-10
 - in medical illness 30(4) 86-8
 - patient support organisations - perinatal depression 31(2) 39
- dermatitis**
 - diagnosis and management of vulvovaginitis in childhood 28(4) 88-90
- dermatology**
 - Therapeutic Guidelines (book review) 32(5) 139; 28(2) 44
- desvenlafaxine**
 - antidepressant - Pristiq (New drug) 32(1) 22-7
 - new drug approvals (PBAC question) 32(3) 63
- Detrusitol**
 - see tolterodine 28(2) 49-51
- dexamphetamine**
 - in attention deficit hyperactivity disorder 31(5) 129-32
- dextromethorphan**
 - precipitating serotonin syndrome 29(3) 71
 - - letter 29(6) 149-50
- diabetes**
 - blood glucose control (editorial) 32(2) 30-1
 - clinical applications of incretins 31(4) 104-8
 - exenatide - type 2 diabetes - Byetta (New drug) 30(6) 163-7
 - exercise 30(5) 130-3
 - - letter 31(1) 3-4
 - foot infections 30(1) 21-4
 - foot ulcers
 - - prevention 31(4) 94-6
 - insulin detemir - Levemir FlexPen (New drug) 28(5) 130-1
 - insulin glulisine - Apidra SoloStar (New drug) 30(5) 133-5
 - metformin in pregnancy and lactation 30(3) 68-9
 - overseas travel and insulin 29(3) 80-2
 - pharmacology of incretins 31(4) 102-4
 - pregabalin - neuropathic pain - Lyrica (New drug) 28(3) 75-9
 - sitagliptin - type 2 diabetes - Januvia (New drug) 31(2) 49-55
 - - letter 31(3) 60-2
 - thiazolidinedione adverse effects (editorial) 31(3) 58-9
- diagnostic tests (see also abnormal laboratory results)**
 - diagnostic imaging
 - - echocardiography 29(5) 134-8
 - - - letter 30(1) 3-4
 - - magnetic resonance imaging in neuroradiology 31(1) 18-20
 - - positron emission tomography 31(5) 123-8
 - - thoracic computed tomography 32(4) 105-7
 - influenza 32(3) 64-7
 - mental status testing in dementia 28(1) 11-3
 - pitfalls in interpretation 32(2) 43-6
 - - letter 32(5) 119-121
 - recurrent deep venous thrombosis 30(2) 38-40
- dienogest/ethinyloestradiol**
 - contraceptive - Valette (New drug) 30(2) 50-5
- diet**
 - lifestyle management of hypertension 31(6) 150-3
 - management of hypercholesterolaemia 31(5) 119-22
 - management of obesity 29(2) 43-7
- digoxin**
 - brands and dosages 29(6) 153
 - - letter 30(2) 32-4
 - therapeutic range (letter) 31(5) 115-8
- Diovan**
 - see valsartan 32(1) 22-7
- dipeptidyl peptidase 4 inhibitors (see also incretins)**
 - clinical applications of incretins 31(4) 104-8
 - pharmacology of incretins 31(4) 102-4
 - sitagliptin - type 2 diabetes - Januvia (New drug) 31(2) 49-55
 - - letter 31(3) 60-2
- Diphereline**
 - see triptorelin embonate 32(1) 22-7
- discharge medication**
 - information and prescriptions (editorial) 29(3) 58-9
 - - letters 29(5) 121
- disease outbreaks**
 - antiviral drugs and influenza prophylaxis 30(2) 30-1
- disodium gadoxetate**
 - liver imaging - Primovist (New drug) 29(3) 84-7
- dizziness**
 - diagnosis and management 28(4) 94-7
 - - dental treatment (letter) 28(6) 136-9
- docetaxel**
 - breast cancer (PBAC question) 30(1) 24-5
- doctor's bag**
 - see emergency supplies 30(6) 143-6
- domiciliary services**
 - chronic obstructive pulmonary disease 30(3) 64-7
- donepezil**
 - Alzheimer's disease (editorial) 28(6) 134-5
 - - letter 29(3) 59-62
- dopamine agonists**
 - cabergoline-induced valvulopathy (medicinal mishap) 31(1) 21
 - in pituitary tumours and prolactinoma 32(1) 19-21
 - pramipexole - Parkinson's disease, restless legs syndrome - Sifrol (New drug) 31(3) 79-83
 - quinagolide - hyperprolactinaemia - Norprolac (New drug) 28(6) 156-8
 - in restless legs syndrome 31(4) 90-3
 - - letter 31(6) 143-5
 - rotigotine - Parkinson's disease - Neupro (New drug) 31(2) 49-55
- Doribax**
 - see doripenem 32(3) 82-6
- doripenem**
 - specified infections - Doribax (New drug) 32(3) 82-6
- Down's syndrome**
 - biochemical tests in pregnancy 29(2) 48-52

driving

- drug therapy and drug abuse 31(2) 33-5

drug abuse

- drugs and road safety 31(2) 33-5
- Drugs of abuse (book review) 29(1) 8
- managing acute pain in opioid dependence 31(5) 133-5
- psychostimulant poisoning 29(4) 109-11

drug allergy

- sulfonamide allergy and cross-reactivity (letter) 32(2) 31

drug bulletins - see drug information**drug compounding**

- in community pharmacy (editorial) 31(2) 30-1
- letter 31(5) 115-8

drug costs - see cost of drugs**drug evaluation**

- appraising medical research 29(5) 122-4
- development of new prescription drugs 29(6) 159-61
- freedom of publication (editorial) 29(5) 120
- letter 30(2) 32-4
- interpreting risks and ratios in clinical trials 31(1) 12-6
- regulation of complementary medicines (editorial) 31(6) 142-3
- surrogate outcome markers in clinical trials 32(2) 47-50
- transparency of information about new drugs
- editorial 28(4) 83-4
- transparency rating 32(3) 80-1; 30(1) 26-7; 28(4) 103
- letter 29(3) 59-62

drug industry (see also advertising)

- 1907 Royal Commission on Secret Drugs, Cures and Foods 30(4) 91
- advertising of complementary medicines (editorial) 31(6) 142-3
- chiral drugs
- correction 28(3) 55-8
- development of new prescription drugs 29(6) 159-61
- direct-to-consumer advertising
- in New Zealand (editorial) 29(2) 30-2
- drug marketing and the internet 32(1) 2-4
- drug promotion and health professionals 30(6) 150-3
- letters 31(3) 60-2
- expensive new drugs (editorials)
- letter 28(3) 55-8
- Medicines Australia
- code of conduct breaches 32(6) 160-1; 31(6) 162-3; 30(6) 153-5; 29(6) 164-5; 29(1) 16-7
- vardenafil 30(6) 154
- patent evergreening (editorial) 29(6) 148-9
- patent expiry and new drug approvals (PBAC question) 32(3) 63
- Powerful medicines (book review) 28(4) 101

- publishing of drug evaluations (editorial) 29(5) 120
- letter 30(2) 32-4
- quality use of generic drugs (editorial)
- letters 28(2) 29-33
- safety and withdrawal of COX inhibitors (editorial) 28(3) 54-5
- starter packs and adverse effects 30(1) 14-6
- transparency of information about new drugs
- editorial 28(4) 83-4
- transparency rating 32(3) 80-1; 30(1) 26-7; 28(4) 103
- letter 29(3) 59-62

drug information

- Australian Medicines Handbook
- book reviews 28(4) 93; 28(2) 41
- Australian Prescriber
- 30th anniversary and history 28(5) 120-2
- letter 29(2) 32-5
- Consumer Medicine Information 30(5) 122-4
- letter 31(2) 32
- declarations of conflict of interest (letter) 29(4) 91-3
- drug labelling and packaging (letter) 28(1) 5-7
- letter 28(4) 84-7
- Goodman & Gilman's The pharmacological basis of therapeutics (book review) 29(1) 25
- hospital discharge medication (editorial) 29(3) 58-9
- letters 29(5) 121
- inadequate consumer drug information sheets (letter) 31(6) 143-5
- Media Doctor 28(1) 13
- publishing of drug evaluations (editorial) 29(5) 120
- letter 30(2) 32-4
- Therapeutic Guidelines
- book reviews
- Dermatology 32(5) 139; 28(2) 44
- Endocrinology 32(6) 151; 28(3) 58
- PDA review - Mini TG (personal digital assistant version) 29(1) 21
- transparency of information about new drugs
- editorial 28(4) 83-4
- transparency rating 32(3) 80-1; 30(1) 26-7; 28(4) 103
- letter 29(3) 59-62
- transparency of the Therapeutic Goods Administration (editorial) 31(5) 114-5

drug interactions

- antiretroviral therapy in HIV infection 28(6) 146-9
- depression in medical illness 30(4) 86-8
- meals and medicines 29(2) 40-2
- polypharmacy (editorial) 31(1) 2-3
- psychotropic drugs and dentistry 30(4) 98-101

- serotonin syndrome with dextromethorphan and citalopram 29(3) 71
- warfarin
- and fenofibrate 29(6) 166
- letter 30(2) 32-4

drug labelling

- aspirin and alcohol 28(1) 18-9
- letter 28(4) 84-7
- consumer information - drug packaging (letters) 28(4) 84-7; 28(1) 5-7
- generic drug names (letter) 28(2) 29-33
- label confusion between Atropin and Azopt (medicinal mishap) 32(5) 138

drug monitoring

- therapeutic
- abnormal laboratory results 31(2) 42-4
- therapeutic range of digoxin (letter) 31(5) 115-8

drug prescribing - see drug therapy; drug utilisation; electronic prescribing**drug promotion - see advertising****drug regulation**

- adverse reaction reporting 28(6) 140-2
- advertising
- direct-to-consumer advertising in New Zealand (editorial) 29(2) 30-2
- efficacy of Ginkgo biloba in tinnitus (letter) 30(2) 32-4
- of complementary medicines (editorial) 31(6) 142-3
- drug compounding in community pharmacy (editorial) 31(2) 30-1
- letter 31(5) 115-8
- drug promotion and health professionals 30(6) 150-3
- pitfalls of prescribing generic drugs (letter) 28(4) 84-7
- quality use of generic drugs (editorial)
- letters 28(2) 29-33
- rifampicin and MRSA infections - Orphan Drug Scheme (letter) 29(1) 3-5
- safety and withdrawal of COX inhibitors (editorial) 28(3) 54-5
- starter packs and drug samples 30(1) 14-6
- surrogate outcome markers in clinical trials 32(2) 47-50
- Therapeutic Goods Administration approval processes 29(6) 159-61
- transparency of information about new drugs
- editorial 28(4) 83-4
- two-way transparency 32(3) 80-1; 30(1) 26-7; 28(4) 103
- letter 29(3) 59-62
- transparency of the Therapeutic Goods Administration (editorial) 31(5) 114-5

drug samples

- starter packs and adverse effects 30(1) 14-6

drug solutions

- compatibilities of parenteral drug solutions 31(4) 98-101
- - letter 31(6) 143-5

drug therapy (items relating to drugs generally)

- Aboriginal patients 28(5) 123-5
- - letters 29(6) 149-50; 29(3) 59-62
- Aboriginal people
- - subsidised medicines 32(5) 121; 31(4) 89
- advice for overseas travellers 29(3) 80-2
- bioequivalence of generic drugs 30(2) 41-3
- - letter 30(4) 88-90
- competency for non-medical prescribers (editorial) 30(3) 58-9
- Consumer Medicine Information 30(5) 122-4
- - letter 31(2) 32
- drug dosage adjustment in kidney disease 30(1) 17-20
- - letter 30(2) 32-4
- drugs and road safety 31(2) 33-5
- evidence-based medicine (editorial) 30(5) 114-5
- expensive drugs and the Pharmaceutical Benefits Scheme (editorial) 29(6) 146-8
- - letter 30(3) 59-63
- expensive new drugs (editorials)
- - letter 28(3) 55-8
- hospital discharge - medication information and prescriptions (editorial) 29(3) 58-9
- - letters 29(5) 121
- meals and medicines 29(2) 40-2
- nurse prescribing
- - editorial 30(1) 2-3
- - letters 31(1) 3-4; 30(4) 88-90
- pharmacotherapy for risk factors 30(2) 47-50
- polypharmacy (editorial) 31(1) 2-3
- prescribing and the law (editorial)
- - letter 28(2) 29-33
- prescribing in liver diseases 32(2) 32-5
- - letters 32(5) 119-121
- risk factor pharmacotherapy (letter) 30(4) 88-90
- starter packs and adverse effects 30(1) 14-6
- US Medicare program (editorial) 32(4) 90-1

drug utilisation

- extended prescribing rights in the UK (editorial) 32(5) 118-9
- statistics - top 10 drugs 32(6) 159; 31(6) 164; 30(6) 142; 29(6) 167; 29(1) 5; 28(2) 37
- undertreatment of cardiovascular diseases in rural populations (editorial) 31(4) 86-7

duloxetine

- Cymbalta - major depression (New drug) 31(3) 79-83

Duratocin

- see carbetocin 30(4) 107-11

dutasteride

- benign prostatic hyperplasia - Avodart (New drug) 32(4) 112-5

DVT - see thromboembolism

dyspepsia

- proton pump inhibitors - long-term management 31(1) 5-7

E

ear

- ear drops and ototoxicity 31(2) 40-1
- otitis media management in children 32(6) 155-9

eating disorders

- treatment with antidepressants 28(4) 91-3

echocardiography

- diagnostic tests 29(5) 134-8
- - letter 30(1) 3-4
- perflutren - contrast medium - Definity (New drug) 30(4) 107-11

ecstasy

- adverse effects 29(4) 109-11

eculizumab

- paroxysmal nocturnal haemoglobinuria - Soliris (New drug) 32(4) 112-5

editorials

- advertising of complementary medicines 31(6) 142-3
- antidepressants
- - suicide risk in children 28(5) 110-1; 28(5) 111-3
- - - letter 29(2) 32-5
- antiviral drugs and influenza prophylaxis 30(2) 30-1
- bioequivalence of biosimilars 32(6) 146-7
- chemotherapy and cancer survival rates 29(1) 2-3
- climate change and infectious diseases 32(3) 58-9
- competency for non-medical prescribers 30(3) 58-9
- depression in medical illness 30(4) 86-8
- direct-to-consumer advertising in New Zealand (editorial) 29(2) 30-2
- donepezil in Alzheimer's disease 28(6) 134-5
- - letter 29(3) 59-62
- drug compounding in community pharmacy 31(2) 30-1
- - letter 31(5) 115-8
- drug patent evergreening 29(6) 148-9
- evidence-based medicine - turning knowledge into action 30(5) 114-5
- expensive drugs and the Pharmaceutical Benefits Scheme 29(6) 146-8
- - letter 30(3) 59-63
- expensive new drugs
- - letter 28(3) 55-8

- extended prescribing rights in the UK 32(5) 118-9
- freedom of publication of drug evaluations 29(5) 120
- - letters 30(2) 32-4
- glucose control in diabetes 32(2) 30-1
- hospital discharge - medication information and prescriptions 29(3) 58-9
- - letters 29(5) 121
- NSAIDs and cardiovascular disease in rheumatology 29(4) 90-1
- nurse prescribing 30(1) 2-3
- - letters 31(1) 3-4; 30(4) 88-90
- Pharmaceutical Benefits Scheme drug price reforms 30(6) 138-40
- polypharmacy 31(1) 2-3
- the polypill and cardiovascular disease 28(4) 82-3
- prescribing and the law
- - letters 28(2) 29-33; 28(2) 29-33
- quality use of generic drugs
- - letters 28(2) 29-33
- safety and withdrawal of COX inhibitors 28(3) 54-5
- salmeterol - safety concerns 29(5) 118-9
- selective serotonin reuptake inhibitors and suicide risk in children 28(5) 111-3
- - letter 29(2) 32-5
- thiazolidinedione adverse effects in diabetes 31(3) 58-9
- transparency of information about new drugs (editorial) 28(4) 83-4
- transparency of the Therapeutic Goods Administration (editorial) 31(5) 114-5
- undertreatment of cardiovascular diseases in rural populations 31(4) 86-7
- US Medicare program and cost of drugs 32(4) 90-1

efalizumab

- in psoriasis 32(1) 14-8
- - update: withdrawal of efalizumab 32(2) 50

- psoriasis - Raptiva (New drug) 28(1) 19-23

eflornithine hydrochloride

- facial hair reduction - Vaniqa (New drug) 29(3) 84-7

eformoterol

- combination inhalers in asthma 28(2) 26-8

Elaprase

- see idursulfase 31(4) 108-11

elderly - see aged

electrocardiography

- Pocket guide to ECGs (book review) 29(4) 93

Emend IV

- see fosaprepitant 31(4) 108-11

Emerflu

- see influenza H5N1 vaccines 32(6) 165-171

emergency contraception

- mifepristone 32(6) 152-4

emergency medicine

- Australian Medicines Handbook - book review 28(2) 41

emergency supplies

- emergency drugs - doctor's bag supplies 30(6) 143-6
- emergency drugs in dentistry 30(6) 146

emtricitabine

- Emtriva - HIV infection (New drug) 28(2) 49-51

Emtriva

- see emtricitabine 28(2) 49-51

Enablex

- see darifenacin hydrobromide 29(5) 138-43

enantiomers

- pharmacology and efficacy
- - correction 28(3) 55-8

endocarditis

- antibiotic prophylaxis
- - dental notes 31(6) 153

endocrinology

- Therapeutic Guidelines - book review 32(6) 151; 28(3) 58

endoscopy

- management of gastrointestinal haemorrhage 28(3) 62-6

enfuvirtide

- pharmacology of HIV fusion inhibitors 31(3) 66-9

England - see United Kingdom

enoxaparin

- heparins in venous thromboembolism prophylaxis 32(4) 108-12

entecavir

- chronic hepatitis B - Baraclude (New drug) 29(5) 138-43

epidemics

- see disease outbreaks 30(2) 30-1

epilepsy (see also anticonvulsants)

- anticonvulsants in pregnancy and breastfeeding 31(3) 70-2
- pregabalin - Lyrica (New drug) 28(3) 75-9
- withdrawal of drugs from seizure-free children 29(1) 18-21

EpiPen

- see adrenaline 29(2) 52-3; 28(4) 90

epplerenone

- heart failure after myocardial infarction - Inspra (New drug) 28(5) 130-1
- - letter 29(2) 32-5

epoetin alfa

- management of anaemia in chronic kidney disease 32(5) 129-131

epoetin beta

- anaemia - NeoRecormon (New drug) 29(4) 112-5
- management of anaemia in chronic kidney disease 32(5) 129-131
- methoxy polyethylene glycol-epoetin beta - anaemia in chronic kidney disease - Mircera (New drug) 32(6) 165-171

Eraxis

- see anidulafungin 32(6) 165-171

Erbix

- see cetuximab 28(4) 104-6

erlotinib

- non-small cell lung cancer - Tarceva (New drug) 29(2) 53-5

erythrocyte sedimentation rate

- C-reactive protein - abnormal laboratory results 30(3) 74-6

erythropoietin

- epoetin beta - anaemia - NeoRecormon (New drug) 29(4) 112-5
- management of anaemia in chronic kidney disease 32(5) 129-131
- methoxy polyethylene glycol-epoetin beta - anaemia in chronic kidney disease - Mircera (New drug) 32(6) 165-171

esomeprazole

- gastrointestinal haemorrhage (letter) 28(6) 136-9

etanercept

- in psoriasis 32(1) 14-8
- tumour necrosis factor blockers in rheumatology 29(3) 67-70

ethics

- drug promotion and health professionals 30(6) 150-3
- - letters 31(3) 60-2

ethinyloestradiol

- dienogest combination - contraceptive - Valette (New drug) 30(2) 50-5

etoricoxib

- analgesia, gout, osteoarthritis - Arcoxia (New drug) 32(5) 142-5

etravirine

- HIV infection - Intelence (New drug) 32(2) 51-5

evergreening

- drug patents (editorial) 29(6) 148-9

everolimus

- Certican - transplantation (New drug) 28(3) 75-9
- pharmacology of immunosuppressants 29(4) 99-101

evidence-based medicine

- appraising medical research 29(5) 122-4
- pharmacotherapy for risk factors 30(2) 47-50
- - letter 30(4) 88-90
- turning knowledge into action (editorial) 30(5) 114-5

exenatide

- clinical applications of incretins 31(4) 104-8
- type 2 diabetes - Byetta (New drug) 30(6) 163-7

exercise

- diabetes 30(5) 130-3
- - letter 31(1) 3-4

exercise testing

- diabetes 30(5) 130-3
- - letter 31(1) 3-4

Exforge

- see amlodipine with valsartan 32(1) 22-7

Exjade

- see deferasirox 29(4) 112-5

experimental pharmacology - see pharmacology

extemporaneous dispensing

- drug compounding in community pharmacy (editorial) 31(2) 30-1
- - letter 31(5) 115-8

eye (see also specific diseases)

- eye drops, correct use 31(1) 16-7
- - letter 31(4) 88-9

F

factor VIII

- inhibitor bypassing fraction - FEIBA-NF - haemophilia (New drug) 30(2) 50-5

Faslodex

- see fulvestrant 30(4) 107-11

FEIBA-NF

- see factor VIII inhibitor bypassing fraction 30(2) 50-5

fenofibrate

- warfarin interactions 29(6) 166
- - letter 30(2) 32-4

fever

- and ciprofloxacin (letter) 28(6) 136-9

fish

- management of venomous puncture injuries 30(5) 117-21
- - letter 31(2) 32

fish oil

- NSAIDs in rheumatology (editorial) 29(4) 90-1

flow cytometry

- abnormal laboratory results 30(5) 128-9

fluorodeoxyglucose

- positron emission tomography 31(5) 123-8

fluoroquinolones

- ear drops and ototoxicity 31(2) 40-1

fluoxetine

- selective serotonin reuptake inhibitors and suicide risk in children (editorial) 28(5) 111-3
- - letter 29(2) 32-5

fluticasone

- combination inhalers in asthma 28(2) 26-8
- corticosteroid therapy in asthma 29(3) 63-6

folic acid

- anticonvulsants in pregnancy and breastfeeding 31(3) 70-2

fondaparinux

- heparins in venous thromboembolism prophylaxis 32(4) 108-12

food

- isomaltulose - sugar substitute - warning in fructose metabolism disorders (letter) 31(1) 3-4
- meals and medicines 29(2) 40-2
- seafood and 'iodine allergy' 32(5) 125-8
- foot infections**
- in diabetes 30(1) 21-4
- foot ulcers**
- prevention 31(4) 94-6
- formularies**
- Australian Medicines Handbook - book reviews 28(4) 93; 28(2) 41
- fosamprenavir**
- Telzir - HIV infection (New drug) 28(1) 19-23
- fosaprepitant**
- emetogenic cancer chemotherapy (New drug) 31(4) 108-11
- Fosrenol**
- see lanthanum carbonate 29(2) 53-5
- fructose metabolism disorders**
- warning about isomaltulose sugar substitute (letter) 31(1) 3-4
- fulvestrant**
- Faslodex - breast cancer (New drug) 30(4) 107-11
- fungal infections**
- posaconazole - Noxafil (New drug) 29(3) 84-7

G

- gadoxetate disodium**
- Primovist - liver imaging (New drug) 29(3) 84-7
- galsulfase**
- mucopolysaccharidosis VI - Naglazyme (New drug) 31(5) 136-9
- Gardasil**
- see human papillomavirus vaccine 29(5) 138-43
- gastro-oesophageal reflux disease**
- proton pump inhibitors
- - long-term management 31(1) 5-7
- gastroenteritis**
- rotavirus vaccine - Rotarix (New drug) 29(4) 112-5
- rotavirus vaccine - RotaTeq (New drug) 29(4) 112-5
- gastroenterology**
- Therapeutic Guidelines - book reviews 30(2) 46
- gastrointestinal haemorrhage**
- aspirin and alcohol 28(1) 18-9
- - letter 28(4) 84-7
- management 28(3) 62-6
- - letter 28(6) 136-9
- paracetamol adverse effects (letter) 30(3) 59-63
- gastrointestinal stromal tumour**
- sunitinib - Sutent (New drug) 29(6) 167-71

- gemcitabine**
- pancreatic carcinoma 28(2) 42-4
- general practice**
- drugs for the doctor's bag 30(6) 143-6
- management of mild depression 28(1) 8-10
- prescribing and the law (editorial)
- - letters 28(2) 29-33
- psychotropic drugs for children and adolescents 28(5) 116-8
- smoking cessation guidelines 28(3) 73-5
- - letter 28(6) 136-9
- generic drugs**
- bioequivalence
- - and pharmacokinetics 30(2) 41-3
- - - letters 30(4) 88-90
- biosimilars are not (bio)generics (editorial) 32(6) 146-7
- patent evergreening (editorial) 29(6) 148-9
- Pharmaceutical Benefits Scheme drug price reforms (editorial) 30(6) 138-40
- pitfalls of prescribing generics (letter) 28(4) 84-7
- quality use (editorial)
- - letters 28(2) 29-33
- geriatric - see aged**
- gingival enlargement**
- drug-induced 29(6) 154-5
- Ginkgo biloba**
- efficacy in tinnitus (editorial) 29(5) 120
- - letter 30(2) 32-4
- glaucoma**
- label confusion between Atropt and Azopt (medicinal mishap) 32(5) 138
- glitazones - see thiazolidinediones**
- global warming - see climate change**
- glomerular filtration rate**
- drug dosage adjustment in kidney disease 30(1) 17-20
- - letter 30(2) 32-4
- glucagon-like peptide-1 agonists (see also incretins)**
- clinical applications of incretins 31(4) 104-8
- pharmacology of incretins 31(4) 102-4
- glucocorticoid receptor antagonists**
- mifepristone 32(6) 152-4
- glucosamine**
- and osteoarthritis (PBAC question) 28(2) 48
- glucose**
- control in diabetes (editorial) 32(2) 30-1
- glycogen storage diseases**
- alglucosidase alfa - Pompe disease - Myozyme (New drug) 31(3) 79-83
- gonorrhoea**
- abnormal laboratory results 30(1) 8-13
- gout**
- etoricoxib - Arcoxia (New drug) 32(5) 142-5
- Great Britain - see United Kingdom**

- guidelines (see also therapeutic guidelines)**
- turning knowledge into action (editorial) 30(5) 114-5
- gum disease - see periodontitis, gingival**
- Gynazole**
- see butoconazole nitrate 29(5) 138-43

H

- haematology**
- diagnostic immunology - abnormal laboratory results 30(5) 128-9
- haematopoietic stem cell transplantation**
- adult leukaemia 29(3) 76-9
- haemodialysis**
- iron sucrose - iron deficiency anaemia - Venofer (New drug) 28(2) 49-51
- - letter 28(4) 84-7
- haemoglobinuria**
- eculizumab - paroxysmal nocturnal haemoglobinuria - Soliris (New drug) 32(4) 112-5
- haemophilia**
- factor VIII inhibitor bypassing fraction - FEIBA-NF (New drug) 30(2) 50-5
- hair growth reduction**
- eflornithine hydrochloride - facial hair - Vaniqa (New drug) 29(3) 84-7
- hay fever - see rhinitis, allergic**
- HDL cholesterol - see cholesterol**
- headache (see also migraine)**
- and analgesic overuse 28(6) 143-5
- - letter 29(3) 59-62
- hearing disorders**
- ear drops and ototoxicity 31(2) 40-1
- heart failure, congestive**
- management in chronic kidney disease 31(6) 154-8
- valsartan - Diovan (New drug) 32(1) 22-7
- heart transplantation**
- everolimus - Certican (New drug) 28(3) 75-9
- heart valve diseases**
- cabergoline-induced valvulopathy (medicinal mishap) 31(1) 21
- Helicobacter pylori**
- proton pump inhibitors - long-term management 31(1) 5-7
- heparins**
- venous thromboembolism prophylaxis 32(4) 108-12
- - and flying 32(6) 148-50
- hepatitis B**
- entecavir - Baraclude (New drug) 29(5) 138-43
- management 32(4) 99-104
- telbivudine - Sebivo (New drug) 30(6) 163-7
- hepatitis C**
- dental notes 29(2) 52
- - letter 30(3) 59-63
- management 29(2) 36-9

- patient support organisation 29(2) 39
- heroin dependence**
- management of acute pain 31(5) 133-5
- herpes simplex**
- genital herpes
- - abnormal laboratory results 30(1) 8-13
- - dental notes 30(1) 13
- herpes zoster**
- vaccine, Zostavax (New drug) 31(1) 24-7
- varicella vaccination (letter) 30(5) 116
- hirsutism**
- eflornithine hydrochloride - facial hair - Vaniqa (New drug) 29(3) 84-7
- histamine H1 antagonists**
- ketotifen - seasonal allergic conjunctivitis - Zaditen (New drug) 28(1) 19-23
- motion sickness prevention in children 32(3) 61-3
- HIV/AIDS**
- abnormal laboratory results 30(1) 8-13
- antiretroviral therapy 28(6) 146-9
- darunavir - Prezista (New drug) 30(3) 79-82
- dental notes 28(6) 149
- emtricitabine - Emtriva (New drug) 28(2) 49-51
- etravirine - Intelence (New drug) 32(2) 51-5
- fosamprenavir - Telzir (New drug) 28(1) 19-23
- maraviroc - Celsentri (New drug) 31(6) 165-7
- pharmacology of HIV fusion inhibitors 31(3) 66-9
- raltegravir - Isentress (New drug) 31(2) 49-55
- tipranavir - Aptivus (New drug) 30(4) 107-11
- hospitals**
- discharge medication - information and prescriptions (editorial) 29(3) 58-9
- - letters 29(5) 121
- prescription drug pricing (letter) 32(3) 60
- human chorionic gonadotrophin**
- biochemical tests for abnormalities in pregnancy 29(2) 48-52
- human papillomavirus vaccine**
- Cervarix (New drug) 30(5) 133-5
- Gardasil (New drug) 29(5) 138-43
- Hunter syndrome**
- idursulfase - Elaprase (New drug) 31(4) 108-11
- hydrochlorothiazide**
- with valsartan - Co-Diovan (New drug) 32(1) 22-7
- hydromorphone**
- Palladone XL (New formulation) 28(3) 75-9
- hyoscine**
- adverse reaction reporting 28(6) 140-2
- motion sickness prevention in children 32(3) 61-3

- hyperactivity disorder in children**
- management 31(5) 129-32
- psychotropic drugs for children in general practice 28(5) 116-8
- hyperaldosteronism**
- abnormal laboratory results 30(6) 147-9
- hypercalcaemia**
- cinacalcet - Sensipar (New drug) 28(3) 75-9
- ibandronic acid - tumour-induced hypercalcaemia - Bondronat (New drug) 31(3) 79-83
- hypercholesterolaemia**
- management 31(5) 119-22
- rosuvastatin - Crestor (New drug) 29(6) 167-71
- hyperlipidaemia (see also antilipidaemic drugs and hypercholesterolaemia)**
- management in chronic kidney disease 31(6) 154-8
- hypermagnesaemia**
- abnormal laboratory results 30(4) 102-5
- hyperparathyroidism**
- cinacalcet - Sensipar (New drug) 28(3) 75-9
- paricalcitol - secondary hyperparathyroidism - Zemplar (New drug) 31(4) 108-11
- hyperphosphataemia**
- lanthanum carbonate hydrate - chronic renal failure - Fosrenol (New drug) 29(2) 53-5
- sevelamer - chronic renal disease -Renagel (New drug) 28(6) 156-8
- hyperprolactinaemia**
- quinagolide - Norprolac (New drug) 28(6) 156-8
- hypersensitivity - see allergy, penicillin allergy**
- hypertension (see also antihypertensives)**
- beta blockers 30(1) 5-7
- - letter 30(3) 59-63
- lifestyle management 31(6) 150-3
- management in chronic kidney disease 31(6) 154-8
- management of uncomplicated hypertension 28(2) 34-7
- - letter 28(5) 113-5
- paracetamol and blood pressure (letter) 30(3) 59-63
- pharmacology of renin inhibitors 32(5) 132-5
- renin inhibitors 32(5) 135-8
- hypertension, pulmonary - see pulmonary hypertension**
- hypnotics**
- adverse effects of zolpidem and zopiclone in insomnia 31(6) 146-9
- hypoglycaemia**
- glucose control in diabetes (editorial) 32(2) 30-1

- hypoglycaemic drugs**
 - clinical applications of incretins 31(4) 104-8
 - exenatide - type 2 diabetes - Byetta (New drug) 30(6) 163-7
 - metformin in pregnancy and lactation 30(3) 68-9
 - pharmacology of incretins 31(4) 102-4
 - hypokalaemia**
 - intravenous potassium chloride fatalities 28(1) 14-6
 - - letters 28(4) 84-7
 - hypomagnesaemia**
 - abnormal laboratory results 30(4) 102-5
 - - letter 30(6) 140-1
 - hyponatraemia**
 - mirtazapine-induced hyponatraemia (medicinal mishap) 31(4) 97
 - - letter 32(1) 5
 - omeprazole 28(2) 48-9
 - tramadol-induced
 - - letter 28(2) 29-33
 - hypothyroidism**
 - thyroid replacement therapy 31(6) 159-61
 - thyroxine administration and pharmacokinetics
 - - shelf-life of thyroxine (letter) 28(1) 5-7
 - - - and refrigeration (letter) 29(2) 32-5
 - hypovolaemia**
 - pentastarch - Voluven (New drug) 30(4) 107-11
-
- I**
-
- If current inhibitors**
 - ivabradine - angina - Corolan (New drug) 30(2) 50-5
 - ibandronic acid**
 - hypercalcaemia, bony metastases of breast cancer - Bondronat (New drug) 31(3) 79-83
 - ibuprofen**
 - paediatric analgesia 31(3) 63-5
 - idursulfase**
 - Hunter syndrome - Elaprase (New drug) 31(4) 108-11
 - imaging - see diagnostic tests or specific method**
 - imatinib**
 - adult leukaemia 29(3) 76-9
 - immunisation - see vaccination**
 - immunocytochemistry**
 - abnormal laboratory results 30(5) 128-9
 - immunophenotyping**
 - abnormal laboratory results 30(5) 128-9
 - immunosuppressants**
 - everolimus - Certican (New drug) 28(3) 75-9
 - experimental and clinical pharmacology 29(4) 99-101; 29(4) 102-8
 - long-term management 32(3) 68-71
 - - dental notes 32(3) 75

- in myasthenia gravis 30(6) 156-60
- impotence - see erectile dysfunction and impotence**
- incretins (see also dipeptidyl peptidase 4 inhibitors, glucagon-like peptide-1 agonists)**
- in diabetes - clinical applications 31(4) 104-8
- in diabetes - pharmacology 31(4) 102-4
- exenatide - type 2 diabetes - Byetta (New drug) 30(6) 163-7
- infants (see also breastfeeding, newborn)**
- abnormal laboratory results - paediatric biochemical tests 28(5) 126-9
- cough and cold remedies 32(5) 122-4
- nitric oxide - neonatal respiratory failure - INOmax (New drug) 31(1) 24-7
- overdoses of over-the-counter drugs in infantile colic 29(3) 83
- poractant alfa - respiratory distress syndrome - Curosurf (New drug) 28(3) 75-9
- treatment of perinatal depression 31(2) 36-9
- infection**
- antibiotics for surgical prophylaxis 28(2) 38-40
- - dental notes 28(2) 41
- climate change and infectious diseases (editorial) 32(3) 58-9
- C-reactive protein - abnormal laboratory results 30(3) 74-6
- management of dental and oral pain 30(3) 77-9
- infertility**
- polycystic ovary syndrome
- - letter 28(3) 55-8
- inflammation**
- C-reactive protein - abnormal laboratory results 30(3) 74-6
- management of dental and oral pain 30(3) 77-9
- monoclonal antibodies 29(5) 130-3
- infliximab**
- in psoriasis 32(1) 14-8
- tumour necrosis factor blockers in rheumatology 29(3) 67-70
- influenza**
- antiviral drugs and influenza prophylaxis (editorial) 30(2) 30-1
- H1N1 vaccine - Panvax H1N1 vaccine (New drug) 32(6) 165-171
- H5N1 vaccines - Pandemrix, Panvax and Emerflu (New drugs) 32(6) 165-171
- rapid diagnostic tests 32(3) 64-7
- seasonal vaccine - Intanza (New drug) 32(6) 165-171
- vaccination
- - for healthy adults 30(2) 35-7
- - - letter 30(5) 116
- - - PBAC question 30(3) 83

- infusions, parenteral**
- compatibilities of drug solutions 31(4) 98-101
- - letter 31(6) 143-5
- inhalation devices**
- combination inhalers 28(2) 26-8
- injections**
- compatibilities of parenteral drug solutions 31(4) 98-101
- - letter 31(6) 143-5
- managing painful paediatric procedures 29(4) 94-6
- - letters 29(6) 149-50
- INOmax**
- see nitric oxide 31(1) 24-7
- insomnia**
- adverse effects of zolpidem and zopiclone 31(6) 146-9
- Inspira**
- see eplerenone 29(2) 32-5; 28(5) 130-1
- insulin detemir**
- diabetes - Levemir FlexPen (New drug) 28(5) 130-1
- insulin glulisine**
- diabetes - Apidra SoloStar (New drug) 30(5) 133-5
- insulin resistance**
- in polycystic ovary syndrome
- - letter 28(3) 55-8
- Intanza**
- see influenza seasonal vaccine 32(6) 165-171
- Intencele**
- see etravirine 32(2) 51-5
- interactions - see drug interactions**
- interferon**
- peginterferon/ribavirin combination in hepatitis C 29(2) 36-9
- pegylated interferon in hepatitis B 32(4) 99-104
- interleukin-6 receptor antagonists**
- tocilizumab - rheumatoid arthritis - Actemra (New drug) 32(4) 112-5
- intermittent claudication**
- cilostazol - Pletal (New drug) 32(3) 82-6
- internet**
- Australian Prescriber website user surveys 30(1) 16
- drug marketing 32(1) 2-4
- interstitial nephritis**
- with omeprazole (medicinal mishap) 30(3) 67
- Invega**
- see paliperidone 31(2) 49-55
- iodine**
- contrast media, seafood and 'iodine allergy' 32(5) 125-8
- irinotecan**
- New brand 28(3) 75-9
- iron deficiency**
- management of anaemia in chronic kidney disease 32(5) 129-131

- iron overload**
- deferasirox - Exjade (New drug) 29(4) 112-5
- iron sucrose**
- Venofer - iron deficiency anaemia in haemodialysis 28(2) 49-51
- - letter 28(4) 84-7
- Isentress**
- see raltegravir 31(2) 49-55
- isomaltulose**
- sugar substitute - warning in fructose metabolism disorders (letter) 31(1) 3-4
- isomerism**
- chiral drugs - pharmacology and efficacy
- - correction 28(3) 55-8
- isotretinoin**
- in acne 28(3) 59-61
- ivabradine**
- angina - Corolan (New drug) 30(2) 50-5

J

- Januvia**
- see sitagliptin (New drug) 31(3) 60-2; 31(2) 49-55
- Japanese encephalitis vaccine**
- Jespect (New drug) 32(3) 82-6
- jaw diseases**
- bisphosphonates and osteonecrosis 30(4) 96-7
- jellyfish**
- management of stings 30(5) 117-21
- - letter 31(2) 32
- Jespect**
- see Japanese encephalitis vaccine 32(3) 82-6

K

- Kepivance**
- see palifermin 28(6) 156-8
- keratinocyte growth factor**
- palifermin - oral mucositis prevention in chemotherapy - Kepivance (New drug) 28(6) 156-8
- ketotifen**
- seasonal allergic conjunctivitis - Zaditen (New drug) 28(1) 19-23
- - correction 28(3) 75-9
- kidney diseases**
- drug dosage adjustment 30(1) 17-20
- - letter 30(2) 32-4
- drug treatment of renal cell cancer 29(6) 151-3
- iron sucrose - iron deficiency anaemia in haemodialysis - Venofer (New drug) 28(2) 49-51
- - letter 28(4) 84-7
- lanthanum carbonate hydrate - hyperphosphataemia in chronic renal failure - Fosrenol (New drug) 29(2) 53-5

- management of anaemia in chronic kidney disease 32(5) 129-131
- managing cardiovascular disease risk in chronic kidney disease 31(6) 154-8
- methoxy polyethylene glycol-epoetin beta - anaemia in chronic kidney disease - Mircera (New drug) 32(6) 165-171
- renal cell cancer
 - drug treatment 29(6) 151-3
- renal cell carcinoma - temsirolimus - Torisel (New drug) 31(4) 108-11
- sevelamer - hyperphosphataemia in chronic renal disease - Renagel (New drug) 28(6) 156-8
- sorafenib - Nexavar - renal cell cancer (New drug) 29(6) 167-71
- sunitinib - Sutent - renal cell cancer (New drug) 29(6) 167-71

kidney failure

- omeprazole and interstitial nephritis 30(3) 67
- paricalcitol - secondary hyperparathyroidism - Zemplar (New drug) 31(4) 108-11

kidney function tests

- drug dosage adjustment in kidney disease 30(1) 17-20
- letter 30(2) 32-4

kidney transplantation

- anti-thymocyte globulin - Thymoglobuline (New drug) 31(5) 136-9
- everolimus - Certican (New drug) 28(3) 75-9

L

laboratory results - see abnormal

laboratory results

lactation - see breastfeeding

lamotrigine

- in bipolar disorders 30(3) 70-3

lanthanum carbonate hydrate

- hyperphosphataemia in chronic renal failure - Fosrenol (New drug) 29(2) 53-5

lapatinib

- breast cancer - Tykerb (New drug) 30(5) 133-5

laronidase

- mucopolysaccharidosis I - Aldurazyme (New drug) 30(3) 79-82

laxatives

- bowel preparation 28(1) 16-7
- methylnaltrexone bromide - opioid-induced constipation - Relistor (New drug) 32(1) 22-7

legal issues

- Disputes and dilemmas in health law - book review 30(4) 105-6
- prescribing and the law (editorial)
- letters 28(2) 29-33
- use of Latin (letters) 28(2) 29-33

- publishing of drug evaluations (editorial) 29(5) 120

- letter 30(2) 32-4

lenalidomide

- multiple myeloma - Revlimid (New drug) 31(2) 49-55
- new drugs for multiple myeloma 32(4) 95-8

leukaemia

- alemtuzumab - chronic lymphocytic leukaemia - MabCampath (New drug) 29(6) 167-71
- arsenic trioxide - acute promyelocytic leukaemia - Phenasen (New drug) 32(5) 142-5
- dasatinib - chronic myeloid and acute lymphoblastic leukaemia - Sprycel (New drug) 30(2) 50-5
- nilotinib - chronic myeloid leukaemia - Tassigna (New drug) 31(2) 49-55
- treatment of adult leukaemia 29(3) 76-9

Levemir FlexPen

- see insulin detemir 28(5) 130-1

LHRH - see luteinising hormone releasing hormone

Li - see lithium

lifestyle-related disease

- management of hypertension, cardiovascular disease 31(6) 150-3

liraglutide

- clinical applications of incretins 31(4) 104-8

lithium

- in bipolar disorders 31(3) 73-6; 30(3) 70-3

liver (see also hepatitis)

- cirrhosis - management of hepatitis B 32(4) 99-104
- clindamycin and hepatotoxicity (medicinal mishap) 32(5) 140
- disodium gadoxetate - Primovist - liver imaging (New drug) 29(3) 84-7
- drug metabolism in liver diseases 32(2) 32-5
- letters 32(5) 119-121
- liver function tests - hepatitis C 29(2) 36-9

liver diseases

- drug prescribing 32(2) 32-5
- letters 32(5) 119-121

Lucentis

- see ranibizumab 30(3) 79-82

lumiracoxib

- analgesia - Prexige (New drug) 29(1) 25-7

lung cancer

- angiogenesis inhibitors 29(1) 13-5
- erlotinib - non-small cell lung cancer - Tarceva (New drug) 29(2) 53-5
- pemetrexed disodium - Alimta (New drug) 28(1) 19-23
- thoracic computed tomography 32(4) 105-7

lung diseases

- management 30(3) 64-7
- letter - alpha-1-antitrypsin deficiency 30(6) 140-1
- patient support organisation 30(3) 79
- thoracic computed tomography 32(4) 105-7

lung function tests

- Pocket guide (book review) 29(3) 70

Lyrica

- see pregabalin 28(3) 75-9

lysosome storage diseases

- galsulfase - mucopolysaccharidosis VI - Naglazyme (New drug) 31(5) 136-9
- idursulfase - Hunter syndrome - Elapraxe (New drug) 31(4) 108-11
- laronidase - mucopolysaccharidosis I - Aldurazyme (New drug) 30(3) 79-82

M

MabCampath

- see alemtuzumab 29(6) 167-71

macular degeneration

- anecortave - Retaane (New drug) 29(2) 53-5
- ranibizumab - Lucentis (New drug) 30(3) 79-82

magnesium

- abnormal laboratory results 30(4) 102-5
- letter 30(6) 140-1

magnetic resonance angiography

- cerebrovascular imaging 31(1) 18-20

magnetic resonance imaging

- disodium gadoxetate - liver imaging - Primovist (New drug) 29(3) 84-7

malaria

- climate change and infectious diseases 32(3) 58-9

manic disorder - see bipolar disorders

maraviroc

- Celsentri - HIV infection (New drug) 31(6) 165-7

Maroteaux-Lamy syndrome

- galsulfase - Naglazyme (New drug) 31(5) 136-9

mass media

- Media Doctor - website review 28(1) 13

Media Doctor

- website review 28(1) 13

media, mass - see mass media

Medicare (United States)

- cost of drugs (editorial) 32(4) 90-1

medicinal mishaps

- bisphosphonates and osteonecrosis of the jaws 30(4) 96-7
- brand confusion with digoxin 29(6) 153
- cabergoline-induced valvulopathy 31(1) 21
- clindamycin and hepatotoxicity 32(5) 140
- cross-reactivity of penicillins and cephalosporins 30(1) 25-6
- dosing errors with infant drops 29(3) 83

- fenofibrate-warfarin interaction 29(6) 166
- hyponatraemia and omeprazole 28(2) 48-9
- interstitial nephritis and omeprazole 30(3) 67
- label confusion between Atropt and Azopt 32(5) 138
- mirtazapine and hyponatraemia 31(4) 97
- - letter 32(1) 5
- morphine dosages in acute pain 32(1) 13
- neutropenia with quetiapine 31(1) 10-1
- serotonin syndrome and over-the-counter medicine 29(3) 71
- 'statins' and muscle symptoms 28(4) 102
- - letter 28(6) 136-9

Medicines Australia (see also under earlier name APMA)

- code of conduct breaches 32(6) 160-1; 31(6) 162-3; 30(6) 153-5; 29(6) 164-5; 29(1) 16-7
- - vardenafil 30(6) 154

memory disorders

- neurocognitive effects of chemotherapy 31(1) 22-4

Meniere's syndrome

- diagnosis and management of dizziness 28(4) 94-7
- patient support organisations 28(4) 107

menstruation

- antidepressants and premenstrual dysphoric disorder 28(4) 91-3

mesothelioma

- pemetrexed disodium - Alimta (New drug) 28(1) 19-23

metformin

- in polycystic ovary syndrome
- - letter 28(3) 55-8
- in pregnancy and lactation 30(3) 68-9

methadone

- dextromethorphan and serotonin syndrome (letter) 29(6) 149-50

methotrexate

- management of patients taking immunosuppressants 32(3) 68-71

methoxy polyethylene glycol-epoetin beta

- anaemia in chronic kidney disease - Mircera (New drug) 32(6) 165-171

methylnaltrexone bromide

- opioid-induced constipation - Relistor (New drug) 32(1) 22-7

methylphenidate

- in attention deficit hyperactivity disorder 31(5) 129-32
- - PBAC questions 31(3) 76

metronidazole

- and breastfeeding (letter) 28(2) 29-33

mifepristone

- clinical overview 32(6) 152-4

migraine

- and analgesic overuse 28(6) 143-5
- - letter 29(3) 59-62

milk, human - see breastfeeding

mini-mental state examination

- mental status testing in dementia 28(1) 11-3

Mircera

- see methoxy polyethylene glycol-epoetin beta 32(6) 165-171

mirtazapine

- mirtazapine-induced hyponatraemia (medicinal mishap) 31(4) 97
- - letter 32(1) 5

monoclonal antibodies

- abciximab - non-malignant disease 29(5) 130-3
- alemtuzumab - chronic lymphocytic leukaemia - MabCampath (New drug) 29(6) 167-71
- basiliximab - non-malignant disease 29(5) 130-3
- bevacizumab - colorectal cancer - Avastin (New drug) 28(4) 104-6
- daclizumab - non-malignant disease 29(5) 130-3
- eculizumab - paroxysmal nocturnal haemoglobinuria - Soliris (New drug) 32(4) 112-5
- efalizumab - psoriasis - Raptiva (New drug) 28(1) 19-23
- muromonab - non-malignant disease 29(5) 130-3
- natalizumab
- - multiple sclerosis - Tysabri (New drug) 30(4) 107-11
- - non-malignant disease 29(5) 130-3
- in non-malignant disease 29(5) 130-3
- panitumumab - metastatic colorectal cancer - Vectibix (New drug) 31(5) 136-9
- ranibizumab - macular degeneration - Lucentis (New drug) 30(3) 79-82
- rituximab - non-malignant disease 29(5) 130-3
- tocilizumab - rheumatoid arthritis - Actemra (New drug) 32(4) 112-5

monoclonal gammopathies

- multiple myeloma screening 32(4) 92-4

morphine

- dosages in acute pain (medicinal mishap) 32(1) 13

motion sickness

- prevention in children 32(3) 61-3

mouth

- drug and radiotherapy-induced xerostomia 29(4) 97-8
- - dental notes 29(4) 108
- - letters 30(1) 3-4
- palifermin - Kepivance (New drug) 28(6) 156-8
- psychotropic drugs and dentistry 30(4) 98-101

mouthwashes

- role in oral hygiene 32(6) 162-4

moxonidine

- hypertension - Physiotens (New drug) 29(1) 25-7

MRI - see magnetic resonance imaging

mucopolysaccharidosis I

- laronidase - Aldurazyme (New drug) 30(3) 79-82

mucopolysaccharidosis II

- idursulfase - Elaprase (New drug) 31(4) 108-11

mucopolysaccharidosis VI

- galsulfase - Naglazyme (New drug) 31(5) 136-9

multiple myeloma

- abnormal laboratory results 32(4) 92-4
- bortezomib - Velcade (New drug) 29(3) 84-7
- lenalidomide - Revlimid (New drug) 31(2) 49-55
- new drugs 32(4) 95-8
- patient support organisation 32(4) 107

multiple sclerosis

- magnetic resonance imaging in neuroradiology 31(1) 18-20
- natalizumab - Tysabri (New drug) 30(4) 107-11

muscle disorders

- and statins 28(4) 102
- - letter 28(6) 136-9

muscle spasticity

- botulinum toxin 32(2) 39-42

muscle symptoms

- with simvastatin (medicinal mishap) 28(4) 102

myasthenia gravis

- Australian Myasthenic Association in NSW 30(6) 160
- - patient support organisations in other states (letter) 31(3) 60-2
- dental notes 30(6) 160
- patient's perspective 30(6) 161
- treatment 30(6) 156-60
- - letters 31(3) 60-2

mycophenolate mofetil

- pharmacology of immunosuppressants 29(4) 99-101; 29(4) 102-8

myeloma - see multiple myeloma

myocardial infarction (see also coronary disease)

- eplerenone - Inspra (New drug) 28(5) 130-1
- - letter 29(2) 32-5

Myozyme

- see alglucosidase alfa 31(3) 79-83

N

Naglazyme

- see galsulfase 31(5) 136-9

nasal decongestants

- over-the-counter medications containing the Sudafed label (letter) 32(3) 60

natalizumab

- multiple sclerosis - Tysabri (New drug) 30(4) 107-11

National Medicines Policy

- quality use of generic drugs (editorial)
- - letters 28(2) 29-33

nausea

- fosaprepitant - cancer chemotherapy - Emend IV (New drug) 31(4) 108-11

necrosis

- spider bites 29(6) 156-8

neonatal - see newborn**NeoRecormon**

- see epoetin beta 29(4) 112-5

neurotoxins

- botulinum toxin in muscle spasticity 32(2) 39-42

nephritis, interstitial

- omeprazole adverse effects 30(3) 67

Neupro

- see rotigotine (New drug) 31(2) 49-55

neuralgia

- drug treatment of neuropathic pain 29(3) 72-5
- post-herpetic - pregabalin - Lyrica (New drug) 28(3) 75-9

neuralgia, trigeminal

- patient support organisation 29(3) 75

neuraminidase inhibitors

- antiviral drugs and influenza prophylaxis (editorial) 30(2) 30-1

neurology

- magnetic resonance imaging in neuroradiology 31(1) 18-20
- Therapeutic Guidelines - book reviews 30(4) 91

neuromuscular blockade

- sugammadex - reversal of neuromuscular blockade by rocuronium or vecuronium - Bridion (New drug) 32(3) 82-6

neuropathic pain

- drug treatment 29(3) 72-5
- - dental notes 29(3) 82
- pregabalin - Lyrica (New drug) 28(3) 75-9

neutraceuticals

- management of hypercholesterolaemia 31(5) 119-22

neutropenia

- quetiapine (medicinal mishap) 31(1) 10-1

New Zealand

- direct-to-consumer advertising (editorial) 29(2) 30-2

newborn

- abnormal laboratory results - paediatric biochemical tests 28(5) 126-9
- nitric oxide - neonatal respiratory failure - INOmax (New drug) 31(1) 24-7
- poractant alfa - respiratory distress syndrome - Curosurf (New drug) 28(3) 75-9

Nexavar

- see sorafenib 29(6) 167-71

nicotine

- varenicline - Champix (New drug) 31(1) 24-7
- - letters 31(5) 115-8; 31(3) 60-2

nicotine replacement therapy

- smoking cessation guidelines 28(3) 73-5
- - letter 28(6) 136-9

nilotinib

- chronic myeloid leukaemia - Tasigna (New drug) 31(2) 49-55

nitisinone

- hereditary tyrosinaemia type 1 - Orfadin (New drug) 32(2) 51-5

nitric oxide

- neonatal respiratory failure - INOmax (New drug) 31(1) 24-7

non-steroidal anti-inflammatory drugs - see anti-inflammatory drugs**Norprolac**

- see quinagolide 28(6) 156-8

Noxafil

- see posaconazole 29(3) 84-7

Nplate

- see romiplostim 31(6) 165-7

NPS - see National Prescribing Service**NSAIDs - see anti-inflammatory drugs****nuclear medicine**

- positron emission tomography 31(5) 123-8

number needed to treat

- interpreting risks and ratios in clinical trials 31(1) 12-6

nurse prescribers

- competency (editorial) 30(3) 58-9
- extended prescribing rights in the UK (editorial) 32(5) 118-9
- prescribing (editorial) 30(1) 2-3
- - letters 31(1) 3-4; 30(4) 88-90

nutrition - see diet**Nyogel**

- see timolol 28(3) 75-9

O

obesity

- management 29(2) 43-7

obstetrics

- carbetocin - prevention of uterine atony after caesarian section - Duratocin (New drug) 30(4) 107-11

oesophagitis - see gastro-oesophageal reflux**off-label prescribing**

- children (editorial)
- - letters 28(1) 5-7

olanzapine

- in bipolar disorders 30(3) 70-3
- in pregnancy and breastfeeding 30(6) 162-3

older persons - see aged**olmesartan medoxomil**

- hypertension - Olmetec (New drug) 30(3) 79-82

Olmetec

- see olmesartan medoxomil 30(3) 79-82

omeprazole

- gastrointestinal haemorrhage (letter) 28(6) 136-9
- and hyponatraemia 28(2) 48-9
- and interstitial nephritis 30(3) 67

oncology - see cancer; antineoplastics**ophthalmic solutions**

- correct use of eye drops 31(1) 16-7
- - letter 31(4) 88-9

opioids

- managing acute pain in opioid dependence 31(5) 133-5
- methylnaltrexone bromide - opioid analgesic-induced constipation - Relistor (New drug) 32(1) 22-7
- neuropathic pain 29(3) 72-5
- in restless legs syndrome 31(4) 90-3

oral contraceptives - see contraceptives**oral hygiene - see dental hygiene****oral mucositis**

- palifermin - Kepivance (New drug) 28(6) 156-8

Orencia

- see abatacept 30(6) 163-7

Orfadin

- see nitisinone 32(2) 51-5

orlistat

- management of obesity 29(2) 43-7

Orphan Drug Scheme

- rifampicin and MRSA infections (letter) 29(1) 3-5

osteoarthritis (see also arthritis)

- etoricoxib - Arcoxia (New drug) 32(5) 142-5
- glucosamine (PBAC question) 28(2) 48
- lumiracoxib - Prexige (New drug) 29(1) 25-7

osteonecrosis

- bisphosphonates and osteonecrosis of the jaws 30(4) 96-7

osteoporosis

- bisphosphonates
- - and osteonecrosis of the jaws 30(4) 96-7
- corticosteroid-induced 31(2) 45-9
- strontium ranelate - Protos (New drug) 28(6) 156-8

otitis media

- in childhood
- - management 32(6) 155-9

over-the-counter medicines

- aspirin, alcohol and gastric bleeding 28(1) 18-9
- - letter 28(4) 84-7
- cold remedy precipitating serotonin syndrome 29(3) 71
- - letter 29(6) 149-50

- cough and cold remedies in children 32(5) 122-4
- medications containing the Sudafed label (letter) 32(3) 60
- overdoses of anticholinergic drugs in infantile colic 29(3) 83
- overactive bladder**
 - darifenacin hydrobromide - Enablex (New drug) 29(5) 138-43
 - solifenacin succinate - Vesicare - (New drug) 29(5) 138-43
 - tolterodine - Detrusitol (New drug) 28(2) 49-51
- overdose**
 - psychostimulant poisoning 29(4) 109-11
- overweight - see obesity**
- ovulation inducers - see fertility drugs**
- oxybutynin**
 - overactive bladder 29(1) 22-4

P

paclitaxel

- breast cancer (PBAC question) 30(1) 24-5

paediatrics - see children

pain

- management in opioid dependence 31(5) 133-5
- management of dental and oral pain 30(3) 77-9
- managing painful paediatric procedures 29(4) 94-6; 29(4) 108
 - letters 29(6) 149-50
- morphine dosages in acute pain (medicinal mishap) 32(1) 13
- neuropathic - drug treatment 29(3) 72-5
 - dental notes 29(3) 82
- paediatric analgesia 31(3) 63-5
 - letters 31(6) 143-5
- perioperative analgesia
 - letter 28(2) 29-33
- pregabalin - neuropathic pain - Lyrica (New drug) 28(3) 75-9

palifermin

- oral mucositis prevention in chemotherapy
 - Kepivance (New drug) 28(6) 156-8

paliperidone

- schizophrenia - Invega (New drug) 31(2) 49-55

Palladone XL

- see hydromorphone 28(3) 75-9

palliative care

- pancreatic carcinoma 28(2) 42-4
- subsidised medicines 31(5) 132
- Therapeutic Guidelines - book review 29(3) 79

pancreatic carcinoma

- chemotherapy 28(2) 42-4

pandemics

- see disease outbreaks 30(2) 30-1

Pandemrix

- see influenza H5N1 vaccines 32(6) 165-171

panitumumab

- metastatic colorectal cancer - Vectibix (New drug) 31(5) 136-9

Panvax

- see influenza H5N1 vaccines 32(6) 165-171

Panvax H1N1 vaccine

- see influenza H1N1 vaccine 32(6) 165-171

papillomavirus vaccine

- Cervarix (New drug) 30(5) 133-5
- Gardasil (New drug) 29(5) 138-43

paracetamol

- gastrointestinal bleeding and hypertension (letter) 30(3) 59-63
- letter 28(2) 29-33
- paediatric analgesia 31(3) 63-5
 - letter 31(6) 143-5

paraproteins

- multiple myeloma screening 32(4) 92-4

parathyroid hormone

- paricalcitol - secondary hyperparathyroidism - Zemplar (New drug) 31(4) 108-11

paricalcitol

- secondary hyperparathyroidism - Zemplar (New drug) 31(4) 108-11

Parkinson's disease

- pramipexole - Sifrol (New drug) 31(3) 79-83
- rotigotine - Neupro (New drug) 31(2) 49-55

paroxetine

- selective serotonin reuptake inhibitors and suicide risk in children (editorial) 28(5) 111-3
 - letter 29(2) 32-5

patents

- evergreening drug patents (editorial) 29(6) 148-9
- patent expiry and new drug approvals (PBAC question) 32(3) 63

pathology, diagnostic - see abnormal

laboratory results

patient compliance

- Aboriginal patients 28(5) 123-5

patient support organisations

- Alzheimer's Australia 28(3) 72
- Anaphylaxis Australia 32(5) 128
- Australian Hepatitis Council 29(2) 39
- Australian Lung Foundation 30(3) 79
- Australian Myasthenic Association in NSW 30(6) 160
 - patient support organisations in other states (letter) 31(3) 60-2
- beyondblue (depression, postnatal depression, anxiety, bipolar disorder) 31(2) 39
- Continence Foundation of Australia 29(1) 24
- Meniere's Support Group 28(4) 107

- Myeloma Foundation of Australia 32(4) 107

- PANDA (perinatal depression) 31(2) 39
- Psoriasis Australia 32(1) 18
- Quitline (smoking cessation) 28(3) 73-5
- Trigeminal Neuralgia Association of Australia 29(3) 75

patient's perspective (see also patient experiences)

- deep vein thrombosis and flying 32(6) 150-1
- myasthenia gravis 30(6) 161

PBAC - see Pharmaceutical Benefits Advisory Committee

PBAC answers to questions

- influenza vaccination 30(3) 83
- patent expiry and new drug approvals 32(3) 63
- specific drugs
 - adrenaline 28(4) 90
 - auto-injectors - repeat prescriptions 28(4) 90
 - shelf-life 29(2) 52-3
 - analgesics and the aged
 - update 28(1) 11-3
- aprepitant as antiemetic in cancer chemotherapy 28(5) 119
- glucosamine and osteoarthritis 28(2) 48
- methylphenidate and attention deficit hyperactivity disorder 31(3) 76
- taxanes and breast cancer 30(1) 24-5

PBS - see Pharmaceutical Benefits Scheme

peginterferon alfa-2a/ribavirin combination

- hepatitis C 29(2) 36-9

peginterferon alfa-2b/ribavirin combination

- hepatitis C 29(2) 36-9

pemetrexed disodium

- lung cancer, mesothelioma - Alimta (New drug) 28(1) 19-23

penicillin allergy

- cephalosporin cross-reactivity 30(1) 25-6

pentastarch

- hypovolaemia - Voluven (New drug) 30(4) 107-11

peptic ulcer

- management of gastrointestinal haemorrhage 28(3) 62-6
 - letter 28(6) 136-9
- proton pump inhibitors - long-term management 31(1) 5-7

peptides

- cyclic citrullinated antibodies in rheumatoid arthritis 29(6) 162-4

perflutren

- ultrasound contrast medium - Definity (New drug) 30(4) 107-11

perindopril

- patent evergreening (editorial) 29(6) 148-9

periodontitis

- adverse drug effects 29(6) 154-5
- dental hygiene for adults 32(3) 72-5
- management of dental and oral pain 30(3) 77-9

peripheral nervous system diseases

- prevention of foot ulcers 31(4) 94-6

peripheral vascular diseases

- prevention of foot ulcers 31(4) 94-6

personal experiences of illness - see**patient's perspective****pertussis**

- management in adults 32(2) 36-8

PET - see positron emission tomography**Pharmaceutical Benefits Scheme**

- comparisons with US Medicare program (editorial) 32(4) 90-1
- drug price reforms (editorial) 30(6) 138-40
- expensive drugs (editorial) 29(6) 146-8
 - letter 30(3) 59-63
- expensive new drugs (editorial)
 - letter 28(3) 55-8
- prescribing and the law (editorial)
 - letters 28(2) 29-33; 28(2) 29-33
- prescription drug pricing 32(1) 6-8
 - letter 32(3) 60
- subsidised medicines for Aboriginal people 32(5) 121; 31(4) 89
- subsidised palliative care medicines 31(5) 132
- transparency of information about new drugs (editorial) 28(4) 83-4

pharmaceutical industry - see drug industry**pharmaceutical promotion - see advertising****pharmacists**

- drug compounding in community pharmacy (editorial) 31(2) 30-1
 - letter 31(5) 115-8
- extended prescribing rights in the UK (editorial) 32(5) 118-9

pharmacogenetics

- warfarin pharmacogenetic testing 32(3) 76-80
 - letter 32(5) 119-121

pharmacokinetics

- chiral drugs
 - correction 28(3) 55-8
 - generic drugs 30(2) 41-3
 - letters 30(4) 88-90
- therapeutic drug monitoring - abnormal laboratory results 31(2) 42-4
 - therapeutic range of digoxin (letter) 31(5) 115-8

pharmacology - experimental and clinical pharmacology

- angiogenesis inhibitors in cancer 29(1) 9-12; 29(1) 13-5
- Goodman & Gilman's The pharmacological basis of therapeutics (book review) 29(1) 25
- HIV fusion inhibitors 31(3) 66-9

- immunosuppressants 29(4) 99-101; 29(4) 102-8
- incretins in diabetes 31(4) 102-4; 31(4) 104-8
- renin inhibitors 32(5) 132-5; 32(5) 135-8
- warfarin pharmacogenetic testing 32(3) 76-80
 - letter 32(5) 119-121

Phenasen

- see arsenic trioxide 32(5) 142-5

phenylephrine

- over-the counter medications containing the Sudafed label (letter) 32(3) 60

phosphate binders

- lanthanum carbonate hydrate - hyperphosphataemia in chronic renal failure - Fosrenol (New drug) 29(2) 53-5

phosphodiesterase inhibitors

- cilostazol - intermittent claudication - Pletal (New drug) 32(3) 82-6

physical activity

- lifestyle management of hypertension 31(6) 150-3

Physiotens

- see moxonidine 29(1) 25-7

pilocarpine

- management of xerostomia 29(4) 97-8
 - letters 30(1) 3-4

pituitary cancer

- drug treatment 32(1) 19-21

plasma volume expanders

- pentastarch - Voluven (New drug) 30(4) 107-11

platelet antagonists

- cilostazol - intermittent claudication - Pletal (New drug) 32(3) 82-6
- coronary stents 30(4) 92-6

Pletal

- see cilostazol 32(3) 82-6

Pocket guide to lung function tests

- book review 29(3) 70

point-of-care tests

- rapid diagnostic tests for influenza 32(3) 64-7

poisoning

- book review - Therapeutic Guidelines: Toxicology & Wilderness 31(6) 164-5
- management of injuries by sea creatures 30(5) 117-21
 - letter 31(2) 32
- snake bites 29(5) 125-9
- spider bites 29(6) 156-8

polycystic ovary syndrome

- drug treatment
 - letter 28(3) 55-8

polypharmacy

- editorial 31(1) 2-3

polypill

- prevention of cardiovascular disease (editorial) 28(4) 82-3

Pompe disease

- alglucosidase alfa - Myozyme (New drug) 31(3) 79-83

poractant alfa

- neonatal respiratory distress syndrome - Curosurf (New drug) 28(3) 75-9

posaconazole

- fungal infections - Noxafil (New drug) 29(3) 84-7

positron emission tomography

- diagnostic tests 31(5) 123-8

postmenopausal symptoms - see menopause**potassium chloride, intravenous**

- adverse effects 28(1) 14-6
 - letter 28(4) 84-7

practice incentives

- in restless legs syndrome 31(4) 90-3

Pradaxa

- see dabigatran etexilate 32(2) 51-5

pramipexole

- Parkinson's disease, restless legs syndrome - Sifrol (New drug) 31(3) 79-83
- in restless legs syndrome 31(4) 90-3

pre-eclampsia

- biochemical tests for abnormalities in pregnancy (letter) 29(4) 91-3

prednisone

- in myasthenia gravis 30(6) 156-60

pregabalin

- epilepsy, neuropathic pain - Lyrica (New drug) 28(3) 75-9

pregnancy (see also birth defects, breastfeeding)

- abnormal laboratory results - biochemical tests 28(4) 98-101
 - letters 29(1) 3-5; 28(6) 136-9
- anticonvulsants 31(3) 70-2
- antidepressants 30(5) 125-7
 - letter 31(2) 32
- antipsychotics 30(6) 162-3
- biochemical tests for abnormalities 29(2) 48-52
 - letter 29(4) 91-3
- metformin and diabetes 30(3) 68-9
- patient support organisations - perinatal depression 31(2) 39
- restless legs syndrome (letter) 31(6) 143-5
- thyroid replacement therapy 31(6) 159-61
- treatment of perinatal depression 31(2) 36-9

premenstrual dysphoric disorder

- treatment with antidepressants 28(4) 91-3

prescribing patterns, costs, etc. - see drug utilisation; cost of drugs**preventative medicine**

- the polypill and cardiovascular disease (editorial) 28(4) 82-3

Prexige

- see lumiracoxib 29(1) 25-7

Prezista

- see darunavir 30(3) 79-82

price of drugs - see cost of drugs**Primovist**

- see disodium gadoxetate 29(3) 84-7

Pristiq

- see desvenlafaxine 32(1) 22-7

progesterone

- inhibitors - mifepristone 32(6) 152-4

prolactinoma

- drug treatment of pituitary tumours 32(1) 19-21

prostatic cancer

- triptorelin embonate – anti androgen - Diphereline (New drug) 32(1) 22-7

prostatic hypertrophy, benign

- dutasteride - Avodart (New drug) 32(4) 112-5

protein C

- congenital protein C deficiency - Ceprotin (New drug) 30(2) 50-5

proton pump inhibitors

- hyponatraemia with omeprazole (medicinal mishap) 28(2) 48-9
- long-term management 31(1) 5-7
- omeprazole and interstitial nephritis 30(3) 67

Protos

- see strontium ranelate 28(6) 156-8

pseudoephedrine

- in myasthenia gravis (letter) 31(3) 60-2
- over-the counter medications containing the Sudafed label (letter) 32(3) 60

psoriasis

- dental notes 32(1) 18
- efalizumab - Raptiva (New drug) 28(1) 19-23
- management of severe psoriasis 32(1) 14-8
- - update: withdrawal of efalizumab 32(2) 50
- patient support organisations 32(1) 18
- tazarotene - Zorac (New drug) 29(3) 84-7

psychotic disorders

- long-term community management 30(2) 44-6

psychotropic drugs

- attention deficit hyperactivity disorder 31(5) 129-32
- in childhood and adolescence 28(5) 116-8
- and dentistry 30(4) 98-101
- Therapeutic Guidelines: Psychotropic (book reviews) 32(2) 42

puberty

- abnormal laboratory results - paediatric biochemical tests 28(5) 126-9

public health

- climate change and infectious diseases (editorial) 32(3) 58-9
- funding of influenza vaccination for healthy adults 30(2) 35-7
- - letter 30(5) 116

pulmonary disease, chronic obstructive

- management 30(3) 64-7
- - letter - alpha-1-antitrypsin deficiency 30(6) 140-1
- patient support organisations 30(3) 79

pulmonary hypertension

- nitric oxide - neonatal respiratory failure - INOmax (New drug) 31(1) 24-7
- sitaxentan - Thelin (New drug) 31(3) 79-83

pulmonary rehabilitation

- chronic obstructive pulmonary disease 30(3) 64-7

purpura

- romiplostim - idiopathic thrombocytopenic purpura - Nplate (New drug) 31(6) 165-7

pyridostigmine

- in myasthenia gravis 30(6) 156-60

Q

QTc interval - see arrhythmia**quality use of medicines - see drug information; drug therapy; drug utilisation****quetiapine**

- neutropenia (medicinal mishap) 31(1) 10-1

quinagolide

- hyperprolactinaemia - Norprolac (New drug) 28(6) 156-8

R

rabies vaccine

- Rabipur (New drug) 29(1) 25-7

Rabipur

- see rabies vaccine 29(1) 25-7

RADAR (Rational Assessment of Drugs and Research)

- risperidone in behavioural disturbances in dementia 28(3) 71

radiology

- bowel preparation 28(1) 16-7

radiotherapy

- salivary glands and xerostomia 29(4) 97-8
- - dental notes 29(4) 108
- - letters 30(1) 3-4

raltegravir

- HIV infection - Isentress (New drug) 31(2) 49-55

ranibizumab

- macular degeneration - Lucentis (New drug) 30(3) 79-82

Raptiva

- see efalizumab 28(1) 19-23

Rational Assessment of Drugs and Research (RADAR) - see RADAR**reference pricing**

- drug price reforms (editorial) 30(6) 138-40

Relistor

- see methylnaltrexone bromide 32(1) 22-7

Renagel

- see sevelamer 28(6) 156-8

renal - see kidney**renin inhibitors**

- in hypertension 32(5) 135-8
- pharmacology 32(5) 132-5

Repreve

- see ropinirole 28(1) 19-23

respiration disorders

- nitric oxide - neonatal respiratory failure - INOmax (New drug) 31(1) 24-7
- Therapeutic Guidelines - book review 28(5) 129

respiratory distress syndrome, neonatal

- poractant alfa - Curosurf (New drug) 28(3) 75-9

restless legs syndrome

- cabergoline-induced valvulopathy (medicinal mishap) 31(1) 21
- diagnosis and management 31(4) 90-3
- - in pregnancy (letter) 31(6) 143-5
- pramipexole - Sifrol (New drug) 31(3) 79-83
- in pregnancy (letter) 31(6) 143-5
- ropinirole - Repreve (New drugs) 28(1) 19-23

Retaane

- see anecortave 29(2) 53-5

retinal disease

- macular degeneration - anecortave - Retaane (New drug) 29(2) 53-5

retinoids

- tazarotene - psoriasis, acne - Zorac (New drug) 29(3) 84-7

Revlimid

- see lenalidomide 31(2) 49-55

rheumatoid arthritis

- abatacept - Orencia (New drug) 30(6) 163-7
- abnormal laboratory results - antibodies to cyclic citrullinated peptides 29(6) 162-4
- tocilizumab - Actemra (New drug) 32(4) 112-5

rheumatoid factor

- abnormal laboratory results - rheumatoid arthritis 29(6) 162-4

rheumatology (see also arthritis; anti-inflammatory drugs)

- NSAIDs and cardiovascular disease (editorial) 29(4) 90-1
- Therapeutic Guidelines - book review 29(5) 124
- tumour necrosis factor blockers 29(3) 67-70
- - letter 28(1) 5-7
- - risk of malignancy (letter) 31(3) 60-2

ribavirin

- peginterferon/ribavirin combination in hepatitis C 29(2) 36-9

rifampicin

- MRSA infections - Orphan Drug Scheme (letter) 29(1) 3-5

risk

- interpreting risks and ratios in clinical trials 31(1) 12-6
- pharmacotherapy for risk factors 30(2) 47-50
- letter 30(4) 88-90

Risperdal

- see risperidone 28(3) 71

risperidone

- in behavioural disturbances in dementia (RADAR comment) 28(3) 71
- paliperidone - risperidone metabolite - schizophrenia - Invega (New drug) 31(2) 49-55

rivaroxaban

- prevention of postoperative venous thrombosis - Xarelto (New drug) 32(1) 22-7

road safety

- drug therapy and drug abuse 31(2) 33-5

rocuronium bromide

- sugammadex - reversal of neuromuscular blockade - Bridion (New drug) 32(3) 82-6

rofecoxib

- vascular effects of COX-2 selective inhibitors
- letter 28(2) 29-33

romiplostim

- idiopathic thrombocytopenic purpura - Nplate (New drug) 31(6) 165-7

ropinirole

- in restless legs syndrome 31(4) 90-3
- restless legs syndrome - Repreve (New drug) 28(1) 19-23

rosuvastatin

- hypercholesterolaemia - Crestor (New drug) 29(6) 167-71

Rotarix

- see rotavirus vaccine 29(4) 112-5

RotaTeq

- see rotavirus vaccine 29(4) 112-5

rotavirus vaccine

- Rotarix (New drug) 29(4) 112-5
- RotaTeq (New drug) 29(4) 112-5

rotigotine

- Parkinson's disease - Neupro (New drug) 31(2) 49-55

rural health

- undertreatment of cardiovascular diseases (editorial) 31(4) 86-7

S

salivary glands

- drug- and radiotherapy-induced xerostomia 29(4) 97-8
- dental notes 29(4) 108
- letters 30(1) 3-4

salmeterol

- combination inhalers in asthma 28(2) 26-8
- safety concerns (editorial) 29(5) 118-9

schizophrenia

- long-term community management 30(2) 44-6
- paliperidone - Invega (New drug) 31(2) 49-55
- ziprasidone - Zeldox (New drug) 30(2) 50-5
- letter 30(3) 59-63

seafood

- 'iodine allergy' 32(5) 125-8

Sebivo

- see telbivudine 30(6) 163-7

sedatives

- psychotropic drugs and dentistry 30(4) 98-101

Sensipar

- see cinacalcet 28(3) 75-9

Septanest

- see articaine 28(1) 19-23

serotonin reuptake inhibitors (see also antidepressant drugs)

- antidepressants and suicide risk in children (editorials) 28(5) 110-1; 28(5) 111-3
- letter 29(2) 32-5
- desvenlafaxine - Pristiq (New drug) 32(1) 22-7
- pregnancy and breastfeeding 30(5) 125-7
- letter 31(2) 32

serotonin syndrome

- over-the-counter dextromethorphan 29(3) 71
- letter 29(6) 149-50

sevelamer

- hyperphosphataemia in chronic renal disease - Renagel (New drug) 28(6) 156-8

sexual abuse

- diagnosis and management of vulvovaginitis in childhood 28(4) 88-90

sexually transmitted infections

- abnormal laboratory results 30(1) 8-13

shingles

- varicella vaccine - frequently asked questions 28(1) 2-5
- letters 28(5) 113-5; 28(3) 55-8
- zoster virus vaccine - Zostavax (New drug) 31(1) 24-7

sialogogues

- management of xerostomia 29(4) 97-8
- letters 30(1) 3-4

sibutramine

- management of obesity 29(2) 43-7

Sifrol

- see pramipexole 31(3) 79-83

simvastatin

- and muscle symptoms 28(4) 102
- letter 28(6) 136-9

sirolimus

- pharmacology of immunosuppressants 29(4) 99-101; 29(4) 102-8

sitagliptin

- clinical applications of incretins 31(4) 104-8

- type 2 diabetes - Januvia (New drug) 31(2) 49-55

- letter 31(3) 60-2

sitaxentan

- pulmonary hypertension - Thelin (New drug) 31(3) 79-83

skin infections

- daptomycin - Cubicin (New drug) 32(2) 51-5

sleep disorders (see also insomnia)

- restless legs syndrome 31(4) 90-3

- letter 31(6) 143-5

sleep-related behaviour

- adverse effects of zolpidem and zopiclone 31(6) 146-9

smallpox

- vaccinia vaccine - ACAM2000 (New drug) 32(6) 165-171

smoking cessation

- guidelines 28(3) 73-5
- letter 28(6) 136-9
- lifestyle management of hypertension 31(6) 150-3
- varenicline - Champix (New drug) 31(1) 24-7
- letters 31(5) 115-8; 31(3) 60-2

snake bites

- management 29(5) 125-9

sodium valproate

- see valproic acid 30(3) 70-3

solifenacin succinate

- overactive bladder - Vesicare (New drug) 29(5) 138-43

Soliris

- see eculizumab 32(4) 112-5

somatostatin analogues

- in pituitary tumours and acromegaly 32(1) 19-21

sorafenib

- renal cell cancer 29(6) 151-3
- renal cell cancer - Nexavar (New drug) 29(6) 167-71

spider bites

- management 29(6) 156-8

Sprycel

- see dasatinib 30(2) 50-5

St John's wort

- in mild depression 28(1) 8-10

staphylococcal infections

- community-acquired methicillin-resistant infection 28(6) 155
- letter 29(3) 59-62
- daptomycin - Staphylococcus aureus bacteraemia - Cubicin (New drug) 32(2) 51-5
- rifampicin and MRSA infections - Orphan Drug Scheme (letter) 29(1) 3-5

starter packs

- adverse effects 30(1) 14-6

statins - see antilipidaemic drugs

statistics

- interpreting risks and ratios in clinical trials 31(1) 12-6

stem cell transplantation

- adult leukaemia 29(3) 76-9

steroids - see corticosteroids**stingrays**

- management of stings 30(5) 117-21
- letter 31(2) 32

stress testing

- diabetes - exercise 30(5) 130-3

stroke - see cerebrovascular disorders**strontium ranelate**

- postmenopausal osteoporosis - Protos (New drug) 28(6) 156-8

Sudafed

- over-the counter medications containing the Sudafed label (letter) 32(3) 60

sugammadex

- reversal of neuromuscular blockade by rocuronium or vecuronium – Bridion (New drug) 32(3) 82-6

suicide

- risk in children (editorials) 28(5) 110-1; 28(5) 111-3
- letter 29(2) 32-5

sulfonamides

- allergy and cross-reactivity 31(1) 8-10
- letters 32(2) 31; 31(4) 88-9

sulfur

- allergy and cross-reactivity 31(1) 8-10
- letters 31(4) 88-9

sunitinib

- gastrointestinal stromal tumour, renal cell cancer - Sutent (New drug) 29(6) 167-71
- renal cell cancer 29(6) 151-3

surgery

- antibiotics for surgical prophylaxis 28(2) 38-40
- dental notes 28(2) 41
- letters 28(5) 113-5; 28(3) 55-8
- blood transfusion guidelines 28(2) 45-7
- perioperative analgesia
- letter 28(2) 29-33

surrogate outcome markers

- clinical trials 32(2) 47-50

Sutent

- see sunitinib 29(6) 167-71

syphilis

- abnormal laboratory results 30(1) 8-13

T

tacrolimus

- pharmacology of immunosuppressants 29(4) 99-101

Tarceva

- see erlotinib 29(2) 53-5

Tasigna

- see nilotinib 31(2) 49-55

taxanes

- breast cancer (PBAC question) 30(1) 24-5

tazarotene

- psoriasis, acne - Zorac (New drug) 29(3) 84-7

telbivudine

- chronic hepatitis B - Sebivo (New drug) 30(6) 163-7

Telzir

- see fosamprenavir 28(1) 19-23

temsirolimus

- renal cell carcinoma - Torisel (New drug) 31(4) 108-11

teratogens - see birth defects**testosterone 5-alpha reductase inhibitors**

- dutasteride - benign prostatic hyperplasia - Avodart (New drug) 32(4) 112-5

tetanus vaccine

- management of animal and human bites 29(1) 6-8

thalassaemia

- deferasirox - chelating agent - Exjade (New drug) 29(4) 112-5

thalidomide (see also lenalidomide)

- angiogenesis inhibitors in cancer 29(1) 9-12
- new drugs for multiple myeloma 32(4) 95-8
- tumour necrosis factor blockers in rheumatoid arthritis (letter) 28(1) 5-7

Thelin

- see sitaxentan (New drug) 31(3) 79-83

Therapeutic Goods Administration

- adverse reaction reporting systems 28(6) 140-2
- rifampicin and MRSA infections - Orphan Drug Scheme (letter) 29(1) 3-5
- transparency of regulatory drug information (editorial) 31(5) 114-5

Therapeutic Guidelines

- book reviews
- Analgesic 31(2) 39
- Antibiotic 30(3) 73
- Cardiovascular 31(6) 158
- Dermatology 32(5) 139; 28(2) 44
- Endocrinology 32(6) 151; 28(3) 58
- Gastrointestinal 30(2) 46
- Neurology 30(4) 91
- Oral and Dental 30(4) 106
- Palliative care 29(3) 79
- Psychotropic 32(2) 42
- Respiratory 28(5) 129
- Rheumatology 29(5) 124
- Toxicology & Wilderness 31(6) 164-5
- PDA review - Mini TG (personal digital assistant version) 29(1) 21

therapeutic guidelines

- antibiotics and endocarditis - dental notes 31(6) 153
- turning knowledge into action (editorial) 30(5) 114-5

thiazolidinediones

- adverse effects in diabetes (editorial) 31(3) 58-9

thrombocytopenia

- idiopathic thrombocytopenic purpura - romiplostim - Nplate (New drug) 31(6) 165-7

thromboembolism

- antiplatelet therapy after coronary stents 30(4) 92-6
- dabigatran etexilate - prevention of postoperative venous thrombosis - Pradaxa (New drug) 32(2) 51-5
- diagnosis of recurrent deep venous thrombosis 30(2) 38-40
- and flying 32(6) 148-50
- patient's perspective 32(6) 150-1
- heparins in venous thromboembolism prophylaxis 32(4) 108-12
- rivaroxaban - prevention of postoperative venous thrombosis – Xarelto (New drug) 32(1) 22-7
- vascular effects of COX-2 selective inhibitors
- letters 28(2) 29-33

thrombolytic drugs - see fibrinolytic drugs; anticoagulants**Thymoglobuline**

- see anti-thymocyte globulin 31(5) 136-9

thyroid function tests

- abnormal laboratory results in pregnancy 28(4) 98-101
- letter 29(1) 3-5
- shelf-life and refrigeration (letters) 29(2) 32-5; 28(1) 5-7
- thyroid replacement therapy 31(6) 159-61

tigecycline

- complicated infections - Tygacil (New drug) 29(5) 138-43

timolol

- new formulation - Timoptol-XE 28(3) 75-9

tininitus

- Ginkgo biloba (editorial) 29(5) 120
- letter 30(2) 32-4

tipranavir

- HIV infection - Aptivus (New drug) 30(4) 107-11

tocilizumab

- rheumatoid arthritis - Actemra (New drug) 32(4) 112-5

tolterodine

- overactive bladder 29(1) 22-4
- letter 29(4) 91-3
- overactive bladder - Detrusitol (New drug) 28(2) 49-51

tomography, X-ray computed

- thoracic 32(4) 105-7

tooth - see dental, dentistry**toothbrushing**

- for adults 32(3) 72-5

top 10 drugs

- statistics 32(6) 159; 31(6) 164; 30(6) 142; 29(6) 167; 29(1) 5; 28(2) 37

Torisel

- see temsirolimus 31(4) 108-11

toxicology

- book review - Therapeutic Guidelines: Toxicology & Wilderness 31(6) 164-5

tramadol

- and hyponatraemia
- - letter 28(2) 29-33
- Tramal oral drops (New formulation) 28(6) 156-8

Tramal

- see tramadol 28(6) 156-8

transparency of information about new drugs - see drug evaluation; drug regulation**transplantation (see also specific organs)**

- everolimus - Certican (New drug) 28(3) 75-9
- immunosuppressants 29(4) 102-8

travel

- climate change and infectious diseases (editorial) 32(3) 58-9
- motion sickness prevention in children 32(3) 61-3
- overseas travel and medicines 29(3) 80-2
- thromboembolism and flying (patient's perspective) 32(6) 150-1
- thromboembolism risk, prophylaxis and flying 32(6) 148-50

tricyclic antidepressants - see antidepressant drugs**trigeminal neuralgia**

- patient support organisation 29(3) 75

triptorelin embonate

- anti androgen - prostate cancer – Diphereline (New drug) 32(1) 22-7

tropical diseases

- climate change and infectious diseases (editorial) 32(3) 58-9

tumour necrosis factor

- monoclonal antibodies 29(5) 130-3

tumour necrosis factor blockers

- rheumatoid arthritis 29(3) 67-70
- - letter 28(1) 5-7
- risk of malignancy (letter) 31(3) 60-2

Tyagacil

- see tigecycline 29(5) 138-43

Tykerb

- see lapatinib 30(5) 133-5

tyrosinaemia

- nitisinone - hereditary tyrosinaemia type 1 - Orfadin (New drug) 32(2) 51-5

tyrosine kinase inhibitors

- dasatinib - chronic myeloid and acute lymphoblastic leukaemia - Sprycel (New drug) 30(2) 50-5
- lapatinib - breast cancer - Tykerb (New drug) 30(5) 133-5
- nilotinib - chronic myeloid leukaemia - Tasigna (New drug) 31(2) 49-55

- renal cell cancer 29(6) 151-3
- sorafenib - renal cell cancer - Nexavar (New drug) 29(6) 167-71
- sunitinib - gastrointestinal stromal tumour, renal cell cancer - Sutent (New drug) 29(6) 167-71

Tysabri

- see natalizumab 30(4) 107-11

U

ulcers

- foot infections in diabetes 30(1) 21-4
- prevention of foot ulcers 31(4) 94-6

ultrasound

- deep venous thrombosis 30(2) 38-40
- echocardiography 29(5) 134-8
- - letter 30(1) 3-4
- perflutren - contrast medium - Definity (New drug) 30(4) 107-11

United Kingdom

- extended prescribing rights (editorial) 32(5) 118-9

United States

- cost of drugs and the Medicare program (editorial) 32(4) 90-1

urinary incontinence

- anticholinergic drugs 29(1) 22-4
- - letter 29(4) 91-3
- tolterodine - Detrusitol (New drug) 28(2) 49-51

V

vaccination (see also injections)

- human papillomavirus
- - Cervarix (New drug) 30(5) 133-5
- - Gardasil (New drug) 29(5) 138-43
- influenza H1N1 vaccine - Panvax H1N1 vaccine (New drug) 32(6) 165-171
- influenza H5N1 vaccines - Pandemrix, Panvax and Emerflu (New drugs) 32(6) 165-171
- influenza seasonal vaccine - Intanza (New drug) 32(6) 165-171
- influenza vaccination for healthy adults 30(2) 35-7
- - letter 30(5) 116
- - PBAC question 30(3) 83
- Japanese encephalitis
- - Jespect (New drug) 32(3) 82-6
- managing painful paediatric procedures 29(4) 94-6
- pertussis - adult and adolescent immunisation 32(2) 36-8
- rabies - Rabipur (New drug) 29(1) 25-7
- rotavirus vaccine - Rotarix (New drug) 29(4) 112-5
- rotavirus vaccine - RotaTaq (New drug) 29(4) 112-5
- specific vaccines - varicella vaccine 28(1) 2-5

- - letters 28(5) 113-5; 28(3) 55-8
- tetanus vaccine in management of animal and human bites 29(1) 6-8
- vaccinia smallpox vaccine - ACAM2000 (New drug) 32(6) 165-171
- varicella
- - vaccination (letter) 30(5) 116
- zoster virus vaccine - Zostavax (New drug) 31(1) 24-7

vaccinia smallpox vaccine

- ACAM2000 (New drug) 32(6) 165-171

Valette

- see dienogest/ethinyloestradiol 30(2) 50-5

valproic acid

- in bipolar disorders 30(3) 70-3
- in pregnancy and breastfeeding 31(3) 70-2

valsartan

- with amlodipine - hypertension - Exforge (New drug) 32(1) 22-7
- with hydrochlorothiazide - hypertension - Co-Diovan (New drug) 32(1) 22-7
- hypertension, heart failure – Diovan (New drug) 32(1) 22-7

Vaniga

- see eflornithine hydrochloride 29(3) 84-7

vardenafil

- advertising - Medicines Australia code of conduct breaches 30(6) 154

varenicline

- Champix - smoking cessation (New drug) 31(1) 24-7
- - letters 31(5) 115-8; 31(3) 60-2

varicella vaccine

- frequently asked questions 28(1) 2-5
- - letters 28(5) 113-5; 28(3) 55-8
- vaccination (letter) 30(5) 116

varices

- management of gastrointestinal haemorrhage 28(3) 62-6

vascular endothelial growth factor

- angiogenesis inhibitors in cancer 29(1) 9-12

vasoconstrictors

- interactions with psychotropic drugs and dentistry 30(4) 98-101

vasodilators

- cilostazol - intermittent claudication - Pletal (New drug) 32(3) 82-6
- nitric oxide - neonatal respiratory failure - INOmax (New drug) 31(1) 24-7

Vectibix

- see panitumumab 31(5) 136-9

vecuronium

- sugammadex - reversal of neuromuscular blockade – Bridion (New drug) 32(3) 82-6

Velcade

- see bortezomib 29(3) 84-7

venlafaxine

- patent expiry and new drug approvals (PBAC question) 32(3) 63

Venofer

- see iron sucrose 28(2) 49-51

venomous fish

- management of puncture injuries 30(5) 117-21
- letter 31(2) 32

venous thrombosis - see thromboembolism**vertigo**

- diagnosis and management 28(4) 94-7
- dental treatment (letter) 28(6) 136-9

Vesicare

- see solifenacin succinate 29(5) 138-43

vestibular disorders

- diagnosis and management of dizziness 28(4) 94-7

vildagliptin

- clinical applications of incretins 31(4) 104-8

vision disorders

- xanthopsia and digoxin dosages 29(6) 153

vitamin D

- prevention of corticosteroid-induced bone loss 31(2) 45-9

vitamin K

- anticonvulsants in pregnancy and breastfeeding 31(3) 70-2
- warfarin pharmacogenetic testing 32(3) 76-80

Voluven

- see pentastarch 30(4) 107-11

vomiting

- fosaprepitant - cancer chemotherapy - Emend IV (New drug) 31(4) 108-11

vulvovaginitis

- butoconazole nitrate - candidal vulvovaginitis - Gynazole (New drug) 29(5) 138-43
- diagnosis and management in childhood 28(4) 88-90

W

wall chart

- anaphylaxis 30(5) 115

warfarin

- bioequivalence of Marevan and Coumadin (letters) 30(2) 32-4
- interactions with fenofibrate 29(6) 166
- letter 30(2) 32-4
- pharmacogenetic testing 32(3) 76-80
- dental notes 32(3) 80
- letter 32(5) 119-121

whooping cough - see pertussis**wilderness medicine**

- book review - Therapeutic Guidelines: Toxicology & Wilderness 31(6) 164-5

wound infections

- antibiotics for surgical prophylaxis 28(2) 38-40
- letters 28(5) 113-5; 28(3) 55-8
- management of animal and human bites 29(1) 6-8

- letters 29(3) 59-62

wounds

- managing painful paediatric procedures 29(4) 94-6
- letters 29(6) 149-50

X

xanthopsia

- digoxin dosages 29(6) 153

Xarelto

- see rivaroxaban 32(1) 22-7

xerostomia

- drug- and radiotherapy-induced 29(4) 97-8
- dental notes 29(4) 97-8
- letters 30(1) 3-4
- psychotropic drugs and dentistry 30(4) 98-101

Y

Z

Zaditen

- see ketotifen 28(1) 19-23

Zeldox

- see ziprasidone 30(3) 59-63; 30(2) 50-5

Zemlar

- see paricalcitol 31(4) 108-11

ziprasidone

- schizophrenia and bipolar I disorder - Zeldox (New drug) 30(2) 50-5
- letter 30(3) 59-63

zolpidem

- adverse effects in insomnia 31(6) 146-9

zopiclone

- adverse effects in insomnia 31(6) 146-9

Zorac

- see tazarotene 29(3) 84-7

Zostavax

- see zoster virus vaccine 31(1) 24-7

zoster virus vaccine

- Zostavax (New drug) 31(1) 24-7

Author Index

- Abbott PV 30(3) 77-9
Abramson M 30(3) 64-7
Adams J 29(1) 2-3
Adsett M 31(1) 21
Al-Sohaily S 31(1) 5-7
Albert E 31(6) 164-5
Allinson YM 28(1) 14-6
Ames D 29(3) 59-62
Amirthanandan S 32(5) 139
Anderson EA 30(1) 25-6
Annetts P 30(3) 83
Arnold T 31(1) 3-4
Aslani P 30(5) 122-4
Attia J 28(6) 134-5
Backhouse P 30(4) 96-7
Baird A 30(6) 143-6
Baird H 32(6) 150-1
Balassa J 29(6) 153
Barbehenn E 28(2) 29-33
Barber N 32(5) 118-9
Barnes D 29(6) 159-61
Bateman GA 31(1) 18-20
Batey R 29(2) 36-9
Bayly P 31(4) 88-9
Beggs S 31(3) 63-5
Bell SJ 32(4) 99-104
Bellchambers H 30(1) 2-3
Bereznicki L 28(4) 84-7
Berk M 31(3) 73-6
Blake G 31(3) 76
Bowden SC 28(1) 11-3
Bowen K 30(1) 21-4
Bownas T 29(2) 32-5
Boyd B 31(1) 3-4
Boyd M 31(3) 66-9
Brand P 28(4) 84-7
Brennan J 28(2) 48
Brodaty H 29(3) 59-62
Broom J 29(1) 6-8
Buchan H 30(5) 114-5
Buckley N 29(4) 109-11
Buckley P 28(2) 44
Buist A 31(2) 36-9
Burrows GD 30(4) 86-8
Byrne GJ 28(3) 67-70
Cai FZJ 29(4) 90-1
Cameron C 29(3) 71
Cameron PD 28(4) 84-7
Campagnaro R 31(5) 115-8
Campbell DJ 32(5) 132-5
Campbell TJ 28(6) 150-4
Canny L 30(3) 59-63
Carapetis JR 28(1) 2-5
Carbonara S 31(1) 3-4
Carter A 30(4) 102-5
Cartwright K 30(5) 128-9
Casey J 30(4) 91
Castellaro P 28(2) 29-33
Cateron ID 29(2) 43-7
Chang A 32(2) 36-8
Cheah C 31(4) 97-97
Cheng A 29(1) 3-5
Choo C 31(1) 10-1
Choo S 28(6) 136-9
Clarke S 29(1) 9-12
Cleland LG 29(4) 90-1
Coates H 31(2) 40-1
Colquhoun D 31(5) 119-22
Commens C 30(6) 140-1; 29(4) 91-3
Corkeron M 31(2) 32-32
Cox I 31(6) 143-5
Cranswick N 32(5) 122-4; 29(3) 83
Crawford G 29(3) 79
Crossing S 31(2) 32-32
Crouch AM 32(1) 9-12
Crowhurst JA 32(3) 60
Dallimore K 29(2) 52-3
Daly CG 32(3) 72-5
Darby I 29(6) 154-5
Davoren P 31(6) 159-61
Day RO 30(3) 59-63; 30(2) 32-4; 29(6) 146-8
Deans K 31(3) 60-2
DeWitt DE 31(4) 86-7
di Paola I 28(3) 55-8
Doogue M 32(5) 119-121
Dooley M 28(6) 136-9
Douglas R 29(6) 149-50
Dowden JS 32(1) 13; 30(6) 154; 30(4) 91; 29(5) 120; 29(1) 25; 28(5) 120-2
Drummer OH 31(2) 33-5
Dubury C 28(4) 84-7
Dugdale P 30(2) 35-7
Duggan A 31(1) 5-7
Duggan K 32(5) 135-8; 31(6) 150-3
Dunlop C 32(5) 138
Dwyer DE 32(3) 64-7
Dwyer S 30(3) 73
Editorial Executive Committee 28(4) 83-4
Elsik M 30(1) 5-7; 29(4) 93
Ewald B 28(5) 113-5
Farah CS 32(6) 162-4; 30(4) 106
Faull R 30(1) 17-20
Faunce T 30(6) 138-40
Feldschuh M 31(2) 30-1
Firkin F 32(6) 148-50; 32(4) 92-4
Fischer G 28(4) 88-90
Fois RA 31(5) 115-8
Foo H 32(3) 64-7
Foster J 31(3) 60-2
Fraser R 28(3) 62-6
French J 30(3) 59-63
Gaetani L 29(5) 121
Gallego G 30(3) 59-63
Gazarian M 28(1) 5-7
Ghiculescu RA 31(2) 42-4; 29(6) 166
Gibbs H 30(2) 38-40
Gillman K 29(4) 91-3; 28(2) 29-33
Glasgow N 30(3) 64-7
Goldman GS 30(5) 116
Goldney RD 29(2) 32-5
Goldstein D 28(2) 42-4
Goss AN 30(4) 96-7; 30(1) 3-4; 28(3) 55-8
Gould-Hurst P 28(2) 29-33
Grabau B 28(3) 55-8
Graham GG 30(3) 59-63; 30(2) 32-4
Grant P 28(4) 84-7
Graudins LV 32(3) 61-3
Greaves R 28(5) 126-9
Greenberg P 31(1) 10-1
Gullotta J 30(4) 88-90
Hague WM 30(3) 68-9
Hall R 28(5) 122
Harman J 31(6) 150-3
Harvey KJ 31(6) 142-3; 30(2) 32-4
Haw C 29(3) 59-62
Hayhow BD 29(5) 122-4
Hazell P 28(5) 116-8
Headrick S 31(1) 21
Healy DL 32(6) 152-4
Heffer R 30(1) 3-4
Hegarty K 28(1) 8-10
Helme RD 29(3) 72-5
Hemming M 28(1) 13
Herriot P 29(5) 121
Hill C 29(3) 67-70
Hill CL 31(3) 60-2
Hill S 28(2) 34-7
Hilmer SN 31(1) 2-3; 29(3) 58-9
Ho J 30(6) 147-9
Honson K 29(3) 59-62
Hope J 30(2) 44-6
Horowitz JD 31(5) 115-8
Horvath N 32(4) 95-8
Hourigan L 29(5) 134-8
Howell C 30(4) 105-6; 28(5) 129
Hsu DC 32(3) 68-71
Huang N 31(6) 150-3
Hunt J 29(6) 149-50
Iannuzzi A 30(2) 46-46
Inglis TJ 32(3) 58-9
Isbister GK 30(5) 117-21; 29(6) 156-8; 29(5) 125-9
Isbister JP 28(2) 45-7
Jackson SL 29(5) 121
James H 29(3) 59-62
James MJ 29(4) 90-1
Jenkins C 29(3) 63-6
Jersmann H 28(6) 136-9
Johnson C 32(2) 42
Johnson D 31(6) 143-5
Johnson DW 31(6) 154-8; 30(2) 32-4
Jones G 30(2) 32-4
Joyner B 28(3) 58
Jureidini JN 28(5) 110-1

Katelaris C 32(5) 125-8; 32(3) 68-71; 31(1) 8-10; 30(1) 25-6
 Katz I 31(3) 60-2
 Kault D 30(4) 88-90
 Kaye K 29(6) 146-8
 Keks NA 30(2) 44-6
 Kelly M 28(1) 5-7
 Kelly MD 28(6) 146-9
 Kennedy D 30(6) 162-3
 Kennedy MA 30(6) 140-1
 Kerr P 28(4) 84-7
 Kerridge I 29(3) 76-9
 Khan SA 29(3) 59-62
 Koh C 32(6) 151
 Komesaroff PA 30(6) 150-3
 Kopp C 29(3) 59-62
 Kostov SH 32(1) 5
 Krum H 30(1) 5-7; 29(2) 32-5
 Kubler P 32(2) 32-5; 29(6) 148-9; 29(5) 124; 28(2) 29-33
 Kuteesa W 29(1) 22-4
 Ladhams B 31(4) 97-97
 Lake P 29(3) 59-62
 Lampe L 28(4) 91-3
 Landau J 31(1) 10-1
 Lander C 31(1) 21
 Lander CM 31(3) 70-2
 Langguth D 29(6) 162-4
 Larkin C 28(5) 123-5
 Latham M 30(6) 161
 Leach AJ 32(6) 155-9
 Lee L 30(1) 17-20
 Lees LA 28(2) 29-33
 Leong A 31(6) 143-5
 Lewis T 30(6) 140-1
 Lim EM 32(1) 19-21
 Litt J 31(5) 115-8; 28(3) 73-5
 Liu C 31(6) 158
 Lofgren H 30(6) 138-40
 Lopert R 32(4) 90-1
 Lowe MP 29(5) 122-4
 Lowinger JS 32(4) 108-12
 Lowy AJ 31(3) 60-2
 Lu CY 32(6) 146-7; 29(6) 146-8
 Lu K 31(1) 10-1
 Lu TYT 29(3) 67-70
 Mackay K 28(6) 140-2
 Mackintosh J 28(2) 48-9
 MacPherson R 31(4) 88-9
 Mainwaring P 29(1) 13-5
 Mangin D 29(2) 30-2
 Mansfield PR 28(2) 29-33
 Marchant J 32(2) 36-8
 Marley J 28(4) 101
 Martin J 31(6) 143-5
 Martin JH 32(5) 119-121; 32(3) 76-80
 Masarei J 32(5) 119-121
 Mathew T 30(2) 32-4
 Maxwell DJ 32(4) 108-12
 May K 31(4) 94-6
 McCann A 30(4) 92-6
 McCormack D 29(4) 109-11
 McCullagh V 28(1) 5-7
 McCullough M 32(6) 162-4; 32(3) 75; 32(3) 80; 32(1) 18; 31(6) 153; 31(5) 136; 30(6) 146; 30(6) 153; 30(6) 160; 30(2) 37-37; 30(2) 43-43; 30(1) 13; 29(4) 108; 29(4) 108; 29(3) 82; 29(2) 52; 28(6) 142; 28(6) 149
 McDonald C 30(3) 64-7
 McGuinness R 31(4) 88-9
 McGuire TM 30(1) 14-6; 28(4) 102
 McIntosh L 32(6) 162-4
 McKinnon RA 32(6) 146-7
 McLachlan A 31(5) 115-8; 30(2) 41-3; 29(2) 40-2
 McLaughlan R 32(3) 60
 McLean A 31(3) 77-9
 McLernon N 28(2) 29-33
 McMillan M 30(1) 2-3
 McPhee J 28(1) 5-7
 Meade CE 28(1) 11-3
 Mewes BT 31(5) 115-8
 Milne RW 30(2) 41-3
 Miners J 32(5) 119-121
 Mitchell PB 30(3) 70-3
 Montanari A 31(6) 143-5; 31(3) 60-2
 Montgomery B 28(4) 93
 Moore KH 29(1) 22-4
 Moro P 30(3) 59-63
 Morris PS 32(6) 155-9
 Morton A 28(6) 136-9; 28(2) 48-9
 Moses GM 28(4) 102
 Munckhof W 28(2) 38-40
 Murney P 31(4) 98-101
 Murray R 28(5) 123-5
 Murray RJ 28(6) 155
 Murtagh JE 29(4) 94-6
 Nandurkar H 32(6) 148-50
 Nash P 31(3) 60-2
 Neeskens P 30(2) 47-50
 Newgreen DB 28(1) 18-9
 Ng CS 30(3) 67
 Ngeow WC 28(5) 113-5
 Nguyen T 32(4) 99-104
 O'Dempsey K 28(3) 55-8
 Ogle SJ 29(3) 58-9
 Olson LG 31(6) 146-9
 Olver I 29(4) 97-8
 Olver JS 30(4) 86-8
 Ooi C 30(1) 8-13
 Osborn M 32(4) 95-8
 Page MM 30(4) 98-101
 Pain MCF 29(3) 70
 Paine M 28(4) 94-7
 Park KEJ 32(2) 30-1
 Pascoe G 28(1) 5-7
 Patounas MP 30(1) 14-6
 Pavlakis N 29(6) 151-3
 Pearce G 30(4) 88-90
 Pearson K 28(4) 90
 Penny B 30(5) 130-3
 Peterson GM 29(5) 121; 28(4) 84-7
 Pett S 31(3) 66-9
 Phillips P 32(2) 43-6
 Pillans P 29(4) 99-101
 Post JJ 28(6) 146-9
 Preda VA 32(1) 14-8
 Prins JB 31(4) 102-4
 Prior F 31(2) 32-32
 Pyle DI 30(3) 70-3
 Rafter N 28(4) 82-3
 Ragg M 31(3) 60-2
 Rahman M 28(6) 136-9
 Ramzan I 31(5) 115-8; 30(2) 41-3; 29(2) 40-2
 Ravan M 31(5) 115-8
 Ravi Kumar A 31(5) 123-8
 Reddel SW 30(6) 156-60
 Reeve J 28(1) 14-6
 Reeves G 30(3) 74-6
 Reutens AT 31(4) 104-8
 Rey JM 28(5) 111-3
 Rice J 28(6) 136-9
 Riminton S 29(5) 130-3
 Roberts LJ 31(5) 133-5
 Roberts S 28(6) 136-9
 Robinson J 29(3) 83
 Rodrigues G 29(3) 59-62
 Roger SD 32(5) 129-131
 Romas E 31(2) 45-9
 Ruse W 28(5) 113-5
 Sarre R 28(1) 16-7
 Scheinberg A 32(2) 39-42
 Schofield P 28(6) 134-5
 Scott I 31(1) 12-6
 Segelov E 29(1) 2-3
 Senanayake S 32(5) 140
 Sharma R 29(1) 9-12
 Shaw JE 31(4) 104-8
 Shenfield GM 31(3) 58-9; 28(3) 54-5
 Siderov J 32(3) 60; 30(1) 24-5; 28(5) 119
 Siebert D 30(2) 30-1
 Simpson G 32(4) 105-7
 Singh A 31(3) 73-6
 Sinha Y 28(4) 84-7
 Sloss A 32(2) 32-5
 Smith AJ 30(3) 58-9; 28(2) 34-7
 Smith RL 29(1) 18-21
 Smith WB 32(5) 125-8; 31(1) 8-10
 Somerville-Brown LM 30(4) 98-101
 Somogyi A 32(5) 119-121; 32(5) 119-121; 29(6) 149-50; 28(3) 55-8
 Steiner M 31(1) 16-7
 Stobie PJ 28(6) 136-9
 Stockigt JR 29(2) 32-5; 29(1) 3-5
 Sullivan JR 32(1) 14-8; 28(3) 59-61
 Sung V 32(5) 122-4
 Sutherland B 32(3) 63

Sved Williams A 30(5) 125-7
Swaminathan S 29(5) 130-3
Sweet M 32(1) 2-4
Tan KS 31(6) 154-8
Tatchell M 32(1) 6-8
Taverner D 29(5) 121
Taylor RJ 28(4) 84-7
Taylor T 29(6) 149-50
Thomas B 29(5) 121
Thyagarajan D 31(4) 90-3
To LB 32(4) 95-8
Tompson A 29(5) 121
Tong WWY 30(1) 25-6
Tonkin AL 28(5) 110-1
Toop L 29(2) 30-2
Torpy DJ 30(6) 147-9
Trabinger J 28(2) 29-33
Tran HA 29(2) 48-52; 28(4)
98-101; 28(2) 29-33
Trevillian P 29(4) 102-8
Twaddell S 32(2) 47-50
Uahwatanasakul W 28(1) 2-5
Van Gool K 30(3) 59-63
Vance A 31(5) 129-32
Vanlint S 31(2) 39
Vardy J 31(1) 22-4
Verras P 28(5) 126-9
Vitry A 31(5) 114-5; 28(2) 29-33
Vivian D 30(3) 59-63
Walker JB 32(2) 31; 30(4) 88-90
Walsh JF 30(1) 3-4
Walters S 30(2) 32-4
Wark PAB 29(5) 118-9
Weatherill C 29(4) 91-3
Weerasuriya K 29(2) 32-5
Weitzel P 32(5) 119-121
Westbury J 31(1) 3-4
Whitehouse M 28(1) 5-7
Wilcox RA 29(1) 21
Wilkinson R 28(2) 41
Williams D 28(6) 143-5
Williams K 30(2) 32-4
Wodak A 29(1) 8
Wong RCW 29(6) 162-4
Wood ML 29(1) 6-8
Woods RG 28(4) 101; 28(3)
54-5; 28(2) 41
Woodward A 28(4) 82-3
Worsnop C 28(2) 26-8
Worthley DL 28(3) 62-6
Wu J 30(4) 102-5
Zaninovich L 30(5) 116
Zwar N 29(3) 80-2